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LONGITUDINAL DATA ANALYSIS IN DEPRESSION STUDIES:
ASSESSMENT OF INTERMEDIATE-OUTCOME-DEPENDENT DYNAMIC
INTERVENTIONS
Yen-Chih Hsu, PhD
University of Pittsburgh, 2011
Longitudinal studies in the treatment of mental diseases, such as chronic forms of major
depressive disorders, frequently use sequential randomization design to investigate treatment
strategies. Outcomes in such studies often consist of repeated measurements of scores, such
as the 24-item Hamilton Rating Scale for Depression, throughout the duration of the therapy.
The goal is to compare different sequences of treatments to find the most beneficial one for
each patient. Note that since treatments are applied sequentially, the eligibility of receiving
one treatment assignment depends on previous treatments and outcomes. Two issues that
make the analysis of data from such sequential designs different from standard longitudinal
data are: (1) the randomization in the subsequent stages for patients who fail to respond
in the previous stage; and (2) the drop-out of patients, for which the assumption of missing
completely at random is usually not realistic. In this dissertation, we show how the inverse-
probability-weighted generalized estimating equations (IPWGEE) method can be used to
draw inference for treatment regimes from two-stage studies. Specifically, we show how to
construct weights and use them in the IPWGEE to derive consistent estimators for the
effects of treatment regimes, and compare them. Large-sample properties of the proposed
estimators are derived analytically, and examined through simulations. We demonstrate our
methods by applying them to a depression dataset.
Public Health Significance: Mental illness is becoming a major public health challenge.
Strategies of multiple treatments have been introduced by many investigators to serve as
iii
an alternative to single strategy in treating patients with chronic depressive disorders. As
the complexity of study design increases, developing sophisticated statistical method is nec-
essary in order to provide valid inference. This dissertation demonstrates the importance
of statistical aspects to estimate the effects of depression treatment regimes from two-stage
longitudinal studies.
Keywords: Counterfactual outcomes, Depression treatment regimes, Generalized estimat-
ing equations, Inverse-probability-weighting, Missing data.
iv
TABLE OF CONTENTS
PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
1.0 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 DYNAMIC TREATMENT REGIMES . . . . . . . . . . . . . . . . . . . . . 1
1.2 SEQUENTIAL RANDOMIZED DESIGN . . . . . . . . . . . . . . . . . . . 2
1.3 COUNTERFACTUAL FRAMEWORK . . . . . . . . . . . . . . . . . . . . 3
1.4 GENERALIZED ESTIMATING EQUATIONS (GEE) . . . . . . . . . . . . 4
1.5 INVERSE-PROBABILITY-WEIGHTING . . . . . . . . . . . . . . . . . . . 5
1.6 REVAMP STUDY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.7 MOTIVATION AND OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . 7
2.0 WEIGHTEDGEE FOR RESPONSE-ADAPTIVE TREATMENT REGIMES
IN TWO-STAGE LONGITUDINAL STUDIES . . . . . . . . . . . . . . . 8
2.1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2 DATA, MODEL, AND ASSUMPTIONS . . . . . . . . . . . . . . . . . . . . 10
2.3 INFERENCE FROM COMPLETE DATA: NO DROP-OUT . . . . . . . . . 13
2.4 INFERENCE FROM INCOMPLETE DATA: PRESENCE OF DROP-OUT 17
2.5 COMPARISON AMONG TREATMENT REGIMES . . . . . . . . . . . . . 21
2.6 SIMULATION STUDY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.7 ANALYSIS OF THE REVAMP DATA . . . . . . . . . . . . . . . . . . . . . 25
2.8 DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.9 FIGURES AND TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
v
3.0 WEIGHTED ESTIMATING EQUATIONS IN TWO-STAGE LONGI-
TUDINAL STUDIES IN THE PRESENCE OF TIME-DEPENDENT
MISSING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.2 MODEL FRAMEWORK AND NOTATION . . . . . . . . . . . . . . . . . . 37
3.3 INFERENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.4 SIMULATION STUDY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.5 ANALYSIS OF THE REVAMP STUDY . . . . . . . . . . . . . . . . . . . . 49
3.6 DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.7 FIGURES AND TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.0 CONCLUSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.1 SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.2 FUTURE WORK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.3 PUBLIC HEALTH SIGNIFICANCE . . . . . . . . . . . . . . . . . . . . . . 63
BIBLIOGRAPHY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
vi
LIST OF TABLES
2.1 Simulation results based on 2000 Monte Carlo samples of size 250. . . . . . . 30
2.2 Simulation results based on 2000 Monte Carlo samples of size 400. . . . . . . 31
2.3 Drop-out rates by baseline characteristics. . . . . . . . . . . . . . . . . . . . . 32
2.4 Estimated effects of treatment regimes in the REVAMP study. . . . . . . . . 33
2.5 Comparisons of the estimated effects of treatment regimes on the HRSD score
for a patient of 43 years controlling for baseline employment status in the
REVAMP study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.1 Simulation results based on 2000 Monte Carlo samples of sizes 250, 500, and
900 with 50% response rate. . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.2 Simulation results based on 2000 Monte Carlo samples of sizes 250, 500, and
900 with 30% response rate. . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.3 Comparisons of subject-specific and time-dependent weights for parameter es-
timation based on 2000 Monte Carlo samples of 50% response rate. . . . . . . 57
3.4 Comparisons of subject-specific and time-dependent weights for parameter es-
timation based on 2000 Monte Carlo samples of 30% response rate. . . . . . . 58
3.5 Drop-out rates by baseline characteristics. . . . . . . . . . . . . . . . . . . . . 59
3.6 Results of estimating the effects of treatment regimes in the REVAMP study
using complete-case and IPWGEE analyses. . . . . . . . . . . . . . . . . . . . 60
3.7 Comparisons of estimated time effects of treatment regimes for a patient of 43
years controlling for employment status in the REVAMP study. . . . . . . . . 61
vii
LIST OF FIGURES
2.1 A study with two-stage design. . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.2 Patient flow in the REVAMP study. . . . . . . . . . . . . . . . . . . . . . . . 29
2.3 The HRSD scores of eight selected patients in the REVAMP study. . . . . . . 29
3.1 Patient flow in the REVAMP study. . . . . . . . . . . . . . . . . . . . . . . . 53
3.2 HRSD scores of patients in the REVAMP study. . . . . . . . . . . . . . . . . 54
viii
PREFACE
I owe my deepest gratitude to my advisor Dr. Abdus S. Wahed for his support and guidance.
I am very fortunate to have him as my dissertation advisor and my Graduate Student
Researcher (GSR) supervisor. He has made available his support in a number of ways.
He is very patient and willing to help students in understanding statistical methodologies,
explaining scientific results, preparing professional presentations, and building my career
path.
It is a pleasure to thank my committee members Dr. Stewart Anderson, Dr. Stephen R.
Wisniewski, and Dr. Joyce Chung-Chou Ho Chang for their valuable time and comments.
Thanks to Dr. Anderson for sharing his experiences and caring my dissertation. This dis-
sertation would not have been accomplished without their assistance. I especially thank
Dr. Wisniewski for generously providing data from the REVAMP study that motivated my
research.
I would like to thank Dr. Chang in many ways. She is not only a committee member of
my dissertation but also my supervisor when I served as a teaching fellow in the Institute
for Clinical Research Education at the University of Pittsburgh for three summers. It is an
honor for me to be a part of her teaching team. Because of this experience, I have learned
how to talk comfortably in front of the audience. That was not an easy job, but I enjoyed it
very much.
I am grateful to Dr. Steven H. Belle for hiring me as a GSR in the Longitudinal Assess-
ment of Bariatric Surgery (LABS) Consortium at the Epidemiology Data Center, University
of Pittsburgh. I have learned so many analytical and communication skills from him. I also
express my appreciation to the personnel in the LABS study including, but not limited to,
Dr. Steven H. Belle, Dr. Abdus S. Wahed, Dr. Wendy C. King, Dr. Faith Selzer, Rocco B.
ix
Mercurio Jr, Deborah E. Martin, Kimberly C. Beringer, Michelle A. Fouse, Laurie K. Iacono,
John J. Gianakas, Abidemi K. Adeniji, Jia-Yuh Chen, and Nick Christian. It is a pleasure
to work with them.
I would like to show my gratitude to all the faculty in the Department of Biostatistics
at the University of Pittsburgh. They have made a great impact on my professional growth.
I am heartily thankful to two past departmental chairs Dr. Howard E. Rockette and Dr.
Gary M. Marsh as well as the present chair Dr. Sally C. Morton who sought funding for me
throughout my doctoral education. Without their efforts, it would have been impossible to
accomplish my goal comfortably. I would also like to thank Dr. Ada O. Youk for reviewing
my manuscript and providing suggestions and comments.
I am indebted to many of my colleagues at the University of Pittsburgh for their support
and encouragement, especially to Abidemi K. Adeniji. Abi is the most dedicated and earnest
student I have even seen. His attitude has an influence on me. I feel very lucky to have a
friend like Abi.
I would like to give my utmost appreciation to my family in Taiwan. My parents have
given me the best education they could have possibly afforded from kindergarten to the
doctorate. I owe them everything and I believe that the completion of this dissertation is
the only way to show them how much I love them and appreciate their support.
No word in any language will be enough to express my debt to my fiance´e Shannon
Hsiang-Yu Chen for her contribution to and understanding of this achievement. We had
shared happiness, anger, grief and joy together for the past four years and will continue
sharing in the future. To me, she is the best gift in my life.
Finally, I sincerely appreciate all who have inspired and encouraged me to follow my
dream. Today, this dream has come true. The completion of the doctorate is not the end
but the beginning: new challenges are ahead of me and waiting for me. With all your
inspiration and encouragement, I have all the strength to face these challenges and conquer
them. I wish you all the best and hope to see you in the future.
July 18, 2011
Pittsburgh
x
1.0 INTRODUCTION
In this chapter, some important concepts that will be repeatedly used in this dissertation
will be reviewed. The topics that will be described briefly here are:
1.1 Dynamic treatment regimes,
1.2 Sequential randomized design,
1.3 Counterfactual framework,
1.4 Generalized estimating equations (GEE),
1.5 Inverse-probability-weighting, and
1.6 REVAMP study.
1.1 DYNAMIC TREATMENT REGIMES
A dynamic treatment regime (DTR), or an adaptive treatment strategy (ATS) is a treatment
rule customized for each individual based on the knowledge of time-dependent treatment, co-
variates and the outcome history [Lavori and Dawson, 2000]. The DTR has become common
in practice for treating patients with complex diseases such as cancer [Thall et al., 2002],
substance abuse [Murphy et al., 2001], and depression [Lavori et al., 2001, TenHave et al.,
2003]. Under the DTR, clinicians choose an initial treatment based on patient’s current and
historical states, make decision for the subsequent treatment based on patient’s intermediate
outcome and history, and repeat the process until achieving the goal of the treatment [Lavori
and Dawson, 2000]. Let t0, t1, · · · , tK be times at which treatment decisions are made. Let
1
the data of covariates and treatments on an individual consist of L0, A0, L1, A1, L2, A2, · · · ,
LK , AK , where
– L0: baseline covariates measured prior to time t0,
– A0: treatment assignment at t0 from a set of potential treatments A0,
– L1: information including intermediate response and other covariates collected after t0
but before t1,
– A1: treatment assignment at t1 from a set of potential treatments A1,
– So forth for Lj and Aj, j=2,· · · ,K.
Also define L¯j = (L0, · · · , Lj) and A¯j = (A0, · · · , Aj) to be cumulative history of covariates
and treatments. A DTR is a function of covariate history and prior treatments, i.e. g :
(T , L¯K) → A¯K such that for every j = 0, · · · , K and for every l¯j ∈ L¯j (l¯j is a realization
of L¯j), g(tj, l¯j) = aj ∈ Aj. For example, in a two-stage design, the data of covariates and
treatments on an individual subject consist of L0, A0, L1, A1, where
– L0 = {age, sex}, L0 = {R, {0, 1}}
– A0 ∈ A0 = {a01, a02},
– L1 = {Response, R}, L1 = {0, 1},
– A1 ∈ A1 = {a11, a12, a′11, a′12}.
Let us consider the DTR “treat with a01; if respond, treat with a11; if not, treat with a
′
11.”
This can be expressed in functional form as
g(t0, l0) = a01 (regardless of covariate values, patients receive a01 at baseline)
g(t1, l0, l1) =
 a11 if l1 = 1 (patients who respond to a01 receive a11 at t1)a′11 if l1 = 0 (patients who do not respond to a01 receive a′11 at t1).
1.2 SEQUENTIAL RANDOMIZED DESIGN
A naive way to compare the effect of the treatment regimes is to randomize patients to all
the possible regimes. However, the number of the decision points, the number of treatments,
or patients’ characteristics can cause the curse of dimensionality, i.e. the number of regimes
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increases rapidly and makes it impossible to randomize patients to all the regimes. Even if
we can list all possible treatment regimes, only a few of them would be viable. Thus, it is
not realistic to randomize patients to all possible regimes. An alternative way is to use the
sequential randomized design [Murphy, 2005] or the “play-the-winner-and-drop-the-loser”
algorithm [Thall et al., 2000] to patients who meet the predetermined criteria. Compared
to the naive design, the sequential randomized design with proper statistical analysis will
provide more efficient and higher power of the estimator for the effect of the regimes [Ko,
2010].
1.3 COUNTERFACTUAL FRAMEWORK
In this dissertation, we use the framework of counterfactuals [Splawa-Neyman, 1990, Rubin,
1974, 1978, Robins, 1986, 1987] to quantify the effect of treatment regimes. Let us consider
a non-time-varying treatment first. Let A denote the treatment, which has two values, 1
and 0. For subject i, let Yi(a) be the potential value of the outcome measurement had the
subject been treated with A = a, a ∈ (0, 1). In practice, a subject can receive only one of
the two treatments, 0 or 1. Thus, one of these two outcomes will be observed in practice.
Therefore, {Yi(1), Yi(0)} are known to be counterfactuals. If each individual could receive
both treatments, one could have estimated the average causal effect of the treatment by the
marginal mean of the outcome
Eˆ {Yi(1)− Yi(0)} =
∑N
i=1 {Yi(1)− Yi(0)}
N
(1.1)
Unfortunately, as stated before, these counterfactuals or potential outcomes cannot be ob-
served for the same subject; i.e., Yi(1) and Yi(0) both cannot be observed for subject i and the
observed data is (Yi, Ai). This is the fundamental problem of causal inference [Holland, 1986].
A number of assumptions [Robins, 1997] allow one to estimate the average causal effect of the
treatment from observed data. We assume that the counterfactual data on subject i do not
depend on the observed or counterfactual data for any other subject [Rubin, 1978, Robins,
1997]. The first assumption is the consistency assumption (CA). The CA is used to connect
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counterfactuals and observed data [Robins, 1997, Robins et al., 2000, Ko et al., 2003]. Under
CA, the observed outcome measurements can be defined as Yi =
∑1
a=0[I(Ai = a) × Yi(a)].
The second assumption is the sequential randomization assumption (SRA) which states
that the probability of receiving treatment Ai = a does not depend on the counterfactual
outcome Yi(a) given the predictor Li, i.e. Yi(a) ⊥⊥ Ai | Li. The SRA is guaranteed in
conditionally randomized studies. Note that in observational studies, since the predictor Li
is unknown, the investigators can only collect as many predictors as possible in order to
approximately satisfy the SRA. Under CA and SRA, E[Yi(1) − Yi(0)] = E[Y¯1 − Y¯2], where
Y¯a =
∑N
i=1[I(Ai = a)Yi]/
∑N
i=1 I(Ai = a) and a ∈ (0, 1). Thus, when CA and SRA are
satisfied, E[Yi(1) − Yi(0)] can be unbiasedly estimated by Y¯1 − Y¯2. The last assumption is
the positivity assumption which states that given the predictor Li, the probability of being
assigned to each possible treatment is greater than zero. In most of the clinical studies, the
positivity is automatically true, because investigators will assign subjects into all treatments
of interest.
1.4 GENERALIZED ESTIMATING EQUATIONS (GEE)
The generalized estimating equations (GEE) approach is one of the well-known statistical
methods to estimate the marginal mean from longitudinal data [Liang and Zeger, 1986, Zeger
and Liang, 1986]. Let Yi = [Yi1, · · · , Yini ]T be a ni × 1 vector of the outcome measurement
for subject i and E(Yi|Xi) = Xiβ be the marginal mean, where Xi = [xi1, · · · ,xini ]T is a
ni× p matrix of covariates and β is a p× 1 vector of parameters, the generalized estimating
equations is given by
n∑
i=1
XTi V
−1
i {Yi −Xiβ} = 0,
where Vi = φA
1
2
i Ri(α)A
1
2
i ; Ri(α) is an ni × ni “working” correlation matrix specified by
a s × 1 vector α; Ai is an ni × ni diagonal matrix with vim(Xi;β) as the m-th element,
where vim(Xi,β) is the assumed working variance function of Yim and φ is the dispersion
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parameter for m ∈ {1, · · · , ni}. The solution of the generalized estimating equations, βˆ, can
be obtained through the iterative Gauss-Newton algorithm:
βˆ
(r+1)
= βˆ
(r)
+
(
n∑
i=1
XTi V˜
−1
i Xi
)
−1 n∑
i=1
XTi V˜
−1
i
{
Yi −Xiβˆ(r)
}
,
where V˜i = Vi[βˆ
(r)
, αˆ{βˆ(r), φˆ(βˆ(r))}].
1.5 INVERSE-PROBABILITY-WEIGHTING
The inverse-probability-weighted estimators were introduced in survey sampling by Horvitz
and Thompson [Horvitz and Thompson, 1952]. To explain the underlying concept, let us
assume that one is interested in estimating the population mean µ = 1
N
∑N
i=1 yi. However,
it is not possible to collect all the data points yi for the entire population of N individuals.
Usual research strategy is to select a sample of individuals, which each i-th selected individual
is based on a known probability pii. The Horvitz-Thompson estimator of the population mean
µ is then µˆ = 1
N
∑N
i=1∆ipi
−1
i yi, where ∆i = 1 if subject i is selected and ∆i = 0 otherwise.
Each selected subject is weighted by pi−1i to represent him/herself and the other pi
−1
i − 1
subjects who are not selected and have similar characteristics. By inversely weighting each
selected subjects, one creates a pseudo-population and calculates the estimator of population
mean as if one has collected data on the entire population. The concept of inverse-probability-
weighting has been adapted by various authors in order to account for the missing data
[Robins and Rotnitsky, 1992, Murphy et al., 2001, Herna´n, 2004, Bembom and van der
Laan, 2008]. In most clinical research, because of treatment assignment or drop-out, not all
subjects will follow a specific regime. One can treat the lack of information as if the data are
missing and use the inverse-probability-weighting method to estimate specific parameters of
interest.
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1.6 REVAMP STUDY
Between 2002 and 2006, the “Research Evaluating the Value of Augmenting Medication with
Psychotherapy (REVAMP)” study [Trivedi et al., 2008] enrolled a total of 808 patients to
determine the role of adjunctive psychotherapy in chronically depressed patients who had
less than complete response to an initial medication. The study consisted of two 12-week
stages. In the first stage, patients were assigned one of four treatments of antidepressants
by the REVAMP physicians based on the algorithm using information on pharmacotherapy
treatment history. These antidepressants were Sertaline (SERT), Escitalopram (EcCIT),
Bupropion (BUP-SR), and Venlafaxine (VLF-XR). After up to 12 weeks of treatment in
the first stage, patients not meeting certain response criteria had their pharmacotherapy
modified based on the pharmacotherapy algorithm and were randomly assigned to one of
three treatment strategies in the second stage: Cognitive Behavioral Analysis System of
Psychotherapy (CBASP) plus medication, Brief Supportive Psychotherapy (BSP) plus med-
ication, and Medication alone (MED). For patients with full response to their antidepressant
in stage one, the same antidepressant was given continuously in stage two. In both stages,
a patient’s 24-item Hamilton Rating Scale for Depression (HRSD) [Hamilton, 1960], was
collected at each visit.
The three specific aims of the REVAMP study were: (1) to compare the efficacy of
adding psychotherapy to a medication change versus changing medication alone (MED) in
chronic depressives with partial response or nonresponse to an initial trial of antidepressant
medication, (2) to test efficacy of the CBASP as an augmentation strategy by comparing
it to BSP, and (3) to test a hypothesized mechanism of therapeutic action of CBASP by
examining whether patients receiving CBASP exhibit significantly greater improvements
in social problem solving than patients receiving BSP or MED. The results from several
studies related to the REVAMP study had suggested the need for multi-stage of sequential
treatments in order to achieve a response [Trivedi et al., 2008, Kocsis et al., 2008, 2009, Klein
et al., 2009].
6
1.7 MOTIVATION AND OBJECTIVES
Sequential randomization design is common in clinical studies. Conventional analysis strat-
egy for data from multi-stage design is to analyze data in separate stages. For example, in a
two-stage design, an initial treatment is given in the first stage and a maintenance (or alter-
nate) treatment is given in the second stage depending on the patient’s response status after
the initial treatment. The estimation and comparison between two maintenance (or alter-
nate) treatments is usually done by conditioning on response to the initial treatment. This
can answer, for example, the question of which alternative treatment is the best for those
who did not respond to the initial treatment. But it does not allow us to answer questions,
such as “which treatment regime is the best for given individual?” In this dissertation, we
propose methods for estimating the effects of dynamic treatment regimes from longitudinal
studies by using the generalized estimating equations and the inverse-probability-weighting
methods.
One of the challenges in analyzing data from longitudinal studies is the presence of
missing data. Most statistical methods for longitudinal data are valid as long as the data
are missing completely at random (MCAR). However, the MCAR assumption may not be
realistic in clinical studies. In contrast, the assumption of missing at random (MAR) is
more persuasive and the unbiased estimates can be obtained through advanced statistical
methods, e.g. inverse-probability-weighting method.
The objective of this dissertation is two-fold: (1) propose statistical methods which
properly accounts for missing data issues for estimating and comparing the effects of dynamic
treatment regimes in longitudinal studies and (2) improve the efficiency of the proposed
estimators by incorporating partially observed information from individuals who have missing
data due to randomization or drop-out.
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2.0 WEIGHTED GEE FOR RESPONSE-ADAPTIVE TREATMENT
REGIMES IN TWO-STAGE LONGITUDINAL STUDIES
2.1 INTRODUCTION
In the past decade, a number of studies have shown the efficacy of pharmacotherapies and
psychotherapies in treatment of chronic forms of major depressive disorders (cMDD). How-
ever, nearly 50% of patients with cMDD fail to respond to the first line pharmacotherapies or
psychotherapies [Kocsis et al., 2009]. Hence, for those who do not respond adequately to the
first line therapy, combining pharmacotherapy and psychotherapy to replace monotherapy
is becoming more and more frequent in clinical practice [Cuijpers et al., 2009]. Combination
treatment, in general, is more expensive than monotherapy. A practical treatment strategy
could be initially giving cMDD patients a common medication, which is usually cheaper,
such as an antidepressant, and adding psychotherapy, which is more expensive, if patients
have poor or partial response to the initial medication. Often, multiple stages of treatments
may be necessary to achieve a response. A patient moves to the next stage of therapy in
two circumstances: (1) if a patient achieves response, the patient could continue the same
therapy or his/her therapy could be modified to maintain the response; and (2) if a patient
fails to respond in the previous stage, the patient would be given some alternative therapies
to achieve a response.
In an attempt to investigate the effect of sequence of pharmacotherapy and psychother-
apy in the treatment of patients with chronic depression, the Research Evaluating the Value
of Augmenting Medication with Psychotherapy (REVAMP) study [Trivedi et al., 2008] en-
rolled a total of 808 patients to determine the role of adjunctive psychotherapy in chroni-
cally depressed patients who had less than complete response to an initial medication. The
8
study consisted of two 12-week stages. In the first stage, patients were assigned one of four
treatments of antidepressants by the REVAMP physicians based on the algorithm using
information on pharmacotherapy treatment history. These antidepressants were Sertaline
(SERT), Escitalopram (EcCIT), Bupropion (BUP-SR), and Venlafaxine (VLF-XR). After
up to 12 weeks of treatment in the first stage, patients not meeting certain response cri-
teria had their pharmacotherapy modified based on the pharmacotherapy algorithm and
were randomly assigned to one of three treatment strategies in the second stage: Cognitive
Behavioral Analysis System of Psychotherapy (CBASP) plus medication, Brief Supportive
Psychotherapy (BSP) plus medication, and Medication alone (MED). For patients with full
response to their antidepressant in the first stage, the same antidepressant was given con-
tinuously in the second stage. In both stages, a patient’s 24-item Hamilton Rating Scale for
Depression (HRSD) score [Hamilton, 1960], was collected at each visit.
The purpose of the REVAMP study was to determine optimal adjunctive psychother-
apies with which chronically depressed patients would benefit most. Since the adjunctive
psychotherapies would be offered only if a chronically depressed patient fails to respond to
the pharmacotherapy, possible choices of treatment regimes would be to continue the same
pharmacotherapy if a patient responds to the therapy and to choose a psychotherapy if
he/she fails to respond to the pharmacotherapy. Since there would be different options of
pharmacotherapies and psychotherapies, the practicing physicians would have to choose from
many different treatment regimes. For example, in the REVAMP study, there were three
possible treatment regimes: (1) treat with an antidepressant, continue the antidepressant
if respond, otherwise add CBASP to the antidepressant; (2) treat with an antidepressant,
continue the antidepressant if respond, otherwise add BSP to the antidepressant; and (3)
treat with an antidepressant, continue the antidepressant if respond, otherwise add MED
alone to the antidepressant. The aim of this study was to compare the efficacy of adding
CBASP or BSP to continued treatment of antidepressants with MED alone. One naive way
to analyze data from such designs would be to compare the psychotherapies conditional on
the fact that the patients did not respond in stage I. However, this would be a conditional
analysis and would not address the question of choosing an overall treatment regime to be
best among all possible regimes.
9
The generalized estimating equations (GEE) approach is one of the well-known statistical
methods to estimate the marginal treatment effect from longitudinal data [Liang and Zeger,
1986, Zeger and Liang, 1986]. In a study with two stages of therapies, such as the REVAMP
study, a patient can belong to several treatment regimes. For example, patients who had
responded to the initial treatment would continue their treatment in the second stage in the
REVAMP study. These patients were treated consistently with all three regimes. Therefore,
the standard GEE may not be directly applicable. Additionally, patients who become eligible
for the second stage treatments receive treatment by randomization and hence, the inverse-
probability-weighted GEE (IPWGEE) [Robins et al., 1995] can be used to account for the
randomization. Moreover, patients may drop out throughout the study. Drop-outs may be
due to lack of efficacy to the pharmacotherapy or psychotherapy. Ignoring these patients
in estimation might lead to biased estimates of effects of treatment regimes [Diggle et al.,
2002]. In this study, we use the IPWGEE to account for drop-outs. We derive consistent and
asymptotically normal estimators of regime effects, and provide the Wald test for comparing
different regimes.
This chapter is organized as follows. We introduce notation, model, and assumptions in
Section 2.2. In Section 2.3, we show how to draw inference from complete data (no drop-
out.) Section 2.4 modifies the estimators from Section 2.3 to account for the drop-outs. The
Wald test statistic for comparing treatment regimes is given in Section 2.5. In Section 2.6,
we evaluate the large-sample properties of the proposed methods through simulations. In
Section 2.7, we demonstrate these methods through an application to the REVAMP dataset.
We wrap up with a discussion in Section 2.8. The figures and tables are listed in Section 2.9.
2.2 DATA, MODEL, AND ASSUMPTIONS
We consider a design that is more general than the REVAMP study (Figure 2.1). We
assume that each patient i (i = 1, . . . , n) randomly receives a first line treatment Aj in
the first stage, where j ∈ {1, . . . , J}. Patients who respond to Aj are randomized to a
maintenance treatment Bk, where k ∈ {1, . . . , K}, and patients who do not respond to Aj
10
are randomized to an alternative treatment B′l, where l ∈ {1, . . . , L}. The objective of this
study is to estimate and compare the effects of various treatment regimes arising from a
combination of the initial treatment, intermediate response, and the second stage treatment.
A treatment regime, AjBkB
′
l, is defined as “treat with Aj followed by Bk if respond, by
B′l if otherwise.” Patients are followed over time, and for patient i, a continuous outcome
Yim (e.g. the 24-item Hamilton Rating Scale for Depression) is measured at time tim, where
m ∈ {1, . . . ,Mi}.
In the presence of randomization and drop-out, it is often useful to apply the idea of
counterfactuals to the data analysis [Holland, 1986]. For patient i (i = 1, . . . , n), define
Ri(Aj) to be the response status if the patient receives the first line treatment Aj; let Tim1i
be the time when patient i is declared a responder or non-responder to the first line treatment
Aj, at which point randomization to the second set of treatment occurs, m1i ∈ {1, . . . ,Mi}.
Whether observed or not, we define the following outcomes: Yi(Aj), a m1i × 1 vector of
repeated measures of outcome at time points in the first stage if patient i receives treatment
Aj in the first stage; Yi(AjBk), a (Mi −m1i) × 1 vector of repeated measures of outcome
at each time point in the second stage if patient i receives treatment Aj in the first stage
and Bk in the second stage after responding to Aj; Yi(AjB
′
l), a (Mi − m1i) × 1 vector of
repeated measures of outcome at each time point in the second stage if patient i receives
treatment Aj in the first stage and B
′
l in the second stage after failing to respond to Aj. For
simplicity, let us assume J = K = L = 2. Thus, for one initial treatment A1, patient i could
be associated with the following random variables:
{[Ri(A1), Tim1i ] ,Yi(A1),Yi(A1B1),Yi(A1B2),Yi(A1B′1),Yi(A1B′2)} . (2.1)
In terms of these counterfactual variables, letYi(A1BkB
′
l) be theMi×1 vector outcome of
patient i under treatment regime A1BkB
′
l, for k, l ∈ {1, 2}. Them-th element of Yi(A1BkB′l)
represents the outcome of patient i at time tim under regime A1BkB
′
l, and it can be expressed
as:
Yim(A1BkB
′
l) = I(tim ≤ Tim1i)Yim(A1)
+ I(tim > Tim1i)
{
RiYi(m−m1i)(A1Bk) + (1−Ri)Yi(m−m1i)(A1B′l)
}
. (2.2)
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In a similar fashion, we can define the outcome, Yim(A2BkB
′
l), for patient i at time tim given
A2BkB
′
l. Therefore, without loss of generality, we will consider one treatment A1 in the first
stage. Our interest is to estimate the effect of treatment regime Yim(A1BkB
′
l) over time,
which is formulated as the coefficient β1,1kl of time in the marginal mean model:
E [Yim(A1BkB
′
l) | xim] = xTimβ1kl, (2.3)
where xTim = [1, tim, w1i, . . . , wpi] and w1i, . . . , wpi are p baseline covariates for patient i.
In other words, we would like to estimate the parameters β1kl = [β0,1kl, . . . , βp+1,1kl]
T . If
Yim(A1BkB
′
l) were observed for each patient in the sample, the generalized estimating equa-
tions could have been used to estimate these coefficients. However, in reality, we cannot
observe the outcome Yim(A1BkB
′
l) for all patients. For example, if a patient receives A1,
responds to A1, and then receives Bk′ where k
′ 6= k, we do not observe Yim(A1BkB′l) for that
patient. The complete observed data are characterized as the set of i.i.d. random list:
{[Ri, Tim1i ] , RiZki, (1−Ri)Z ′li,Wi,Yi} , k, l = 1, 2, i = 1, . . . , n,
where Ri = 1, if the patient is a responder, and Ri = 0, if otherwise;Wi = [W1i, . . . ,Wpi]
T is
a p×1 vector of p baseline covariates; Zki and Z ′li are the assignment indicators for treatment
Bk and B
′
l, respectively, for k, l ∈ {1, 2}; Z1i = 1(0) if patient i is randomized to B1(B2);
Z ′1i = 1(0) if patient i is randomized to B
′
1(B
′
2); Z2i and Z
′
2i satisfy Z1i + Z2i = 1 and
Z ′1i + Z
′
2i = 1; Yi is a Mi × 1 vector of repeated observed outcome for patient i.
In order to draw inference on Yi(A1BkB
′
l) from observed data, the consistency assump-
tion (CA) is required to connect observed data and counterfactuals [Rubin, 1974, Robins
et al., 2000]. The CA implies that the observed outcome is equal to the counterfactual out-
come under treatment assignment consistent with the counterfactual. In other words, for
m ∈ {1, 2, . . . ,Mi},
Yim = I(tim ≤ Tim1i)Yim(A1)
+ I(tim > Tim1i)
{
Ri
2∑
k=1
ZkiYi(m−m1i)(A1Bk) + (1−Ri)
2∑
l=1
Z ′liYi(m−m1i)(A1B
′
l)
}
. (2.4)
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Another frequently made assumption is the Sequential Randomization Assumption (SRA)
which states that the probabilities of receiving treatment Bk and B
′
l do not depend on coun-
terfactuals given the history of information collected prior to the randomization [Rubin,
1974, Robins, 1986]:
P {Zki = 1 | [Ri = 1, Tim1i ] ,Wi,Yi(A1BkB′l)} = P {Zki = 1 | [Ri = 1, Tim1i ] ,Wi} ;
P {Z ′li = 1 | [Ri = 0, Tim1i ] ,Wi,Yi(A1BkB′l)} = P {Z ′li = 1 | [Ri = 0, Tim1i ] ,Wi} ;
for k, l ∈ {1, 2}. (2.5)
In the REVAMP study, the probabilities of treatment assignment in the second stage were
constant. Therefore, we define P{Zki = 1 | [Ri = 1, Tim1i ],Wi} = ηk and P{Z ′li = 1 | [Ri =
0, Tim1i ],Wi} = ζl.
2.3 INFERENCE FROM COMPLETE DATA: NO DROP-OUT
If everyone in our sample had followed the same treatment regime A1BkB
′
l, where k, l ∈
{1, 2}, we could have used the GEE method [Liang and Zeger, 1986, Zeger and Liang, 1986] to
estimate the regime effect, i.e. a (p+2)×1 vector of parameter β1kl = [β0,1kl, β1,1kl, . . . , βp+1,1kl]T .
The generalized estimating equations in this case would be given by
n∑
i=1
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl} = 0, (2.6)
where XTi = [xi1, . . . ,xiMi ], and x
T
im = [1, tim,W
T
i ], where m ∈ {1, 2, . . . ,Mi}; R(α) is an
Mi ×Mi “working” correlation matrix specified by α; Ai,1kl is an Mi ×Mi diagonal matrix
with vim(Xi;β1kl) as the m-th element, where vim(Xi,β1kl) is the assumed working variance
function of Yim(A1BkB
′
l) and φ is the dispersion parameter; Vi,1kl = φA
1
2
i,1klR(α)A
1
2
i,1kl.
However, not all patients followed the treatment regime A1BkB
′
l. Some patients in the
study received treatments inconsistent with A1BkB
′
l, i.e. these patients randomized to re-
ceive other second stage treatment B3−k or B
′
3−l, where k, l ∈ {1, 2}. The data from these
patients can be treated as missing data while estimating β1kl. Because of randomization,
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these patients with treatments inconsistent with A1BkB
′
l are similar to those treated un-
der treatment regime A1BkB
′
l. Thus, the inverse-probability-weighted method [Horvitz and
Thompson, 1952, Rosenbaum and Rubin, 1983] can be used to account for the data that are
missing by randomization. Patients randomized to treatment Bk are weighted by 1/ηk and
patients randomized to treatment B′l are weighted by 1/ζl. This way, a patient randomized
to treatment Bk or B
′
l counts for him/herself as well as for (1/ηk − 1) or (1/ζk − 1) similar
patients who have “missing data” with respect to treatment regime A1BkB
′
l (i.e. random-
ized to a second stage treatment other than Bk or B
′
l.) This inverse probability of treatment
weighting will be applied to create a pseudo-population from each patient who follows the
policy A1BkB
′
l. The weight, Qi,1kl, is thus defined to be an Mi ×Mi diagonal matrix with
each m-th diagonal element, Qim,1kl, defined as[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
]
.
Given the treatment regime A1BkB
′
l, we use the IPWGEE method [Robins et al., 1995] with
the “weight” Qi,1kl to estimate the regime effect β1kl. The weighted estimating equation is
then
n∑
i=1
Ui (β1kl) =
n∑
i=1
XTi V
−1
i,1klQi,1kl {Yi −Xiβ1kl} = 0, (2.7)
where Yi, Xi, and Vi,1kl are defined as in (2.6). The solution of (2.7), βˆ1kl, can be obtained
through the following iterative algorithm [Liang and Zeger, 1986]:
βˆ
(r+1)
1kl = βˆ
(r)
1kl +
(
n∑
i=1
XTi V
−1
i,1klQi,1klXi
)
−1 n∑
i=1
XTi V
−1
i,1klQi,1kl
{
Yi −Xiβˆ(r)1kl
}
. (2.8)
Lemma 2.3.1. Under SRA in (2.5), E[Qi,1kl | Xi,Yi(A1BkB′l)] = IMi.
Proof. This follows since
E [Qim,1kl | Xi,Yi(A1BkB′l)]
= E
{
E
[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
| Ri,Xi,Yi(A1BkB′l)
]}
= E
{
Ri
ηk
E [Zki | Ri,Xi,Yi(A1BkB′l)] +
1−Ri
ζl
E [Z ′li | Ri,Xi,Yi(A1BkB′l)]
}
= 1 (by SRA), for m ∈ {1, . . . ,Mi}.
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Proposition 2.3.1. Under CA in (2.4) and SRA in (2.5), βˆ1kl is a consistent estimator of
β1kl.
Proof. First note that by CA in (2.4), Qi,1klYi = Qi,1klYi(A1BkB
′
l). Also note that βˆ1kl
satisfies Equation (2.7), and therefore, to show that βˆ1kl is consistent, it suffices to show
that E[Ui(β1kl)] = 0. Now,
E [Ui (β1kl)] = E
[
XTi V
−1
i,1klQi,1kl {Yi −Xiβ1kl}
]
= E
[
XTi V
−1
i,1klQi,1kl {Yi(A1BkB′l)−Xiβ1kl}
]
(by CA in (2.4))
= E
{
E
[
XTi V
−1
i,1klQi,1kl {Yi(A1BkB′l)−Xiβ1kl} | Xi,Yi(A1BkB′l)
]}
= E
[
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl}
]
(by Lemma 2.3.1)
= E
{
E
[
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl} | Xi
]}
= E
{
XTi V
−1
i,1kl {E [Yi(A1BkB′l) | Xi]−Xiβ1kl}
}
= 0 (by Equation (2.3)).
Proposition 2.3.2. Under CA in (2.4) and SRA in (2.5), βˆ1kl is asymptotically normally
distributed with mean β1kl and variance Σ/n, where
Σ = C−1(φ,α,β1kl)B(φ,α,β1kl)C
−1(φ,α,β1kl),
C(φ,α,β1kl) = E
[
XTi V
−1
i,1klXi
]
, and
B(φ,α,β1kl) = E
[
XTi V
−1
i,1klQi,1kl {Yi −Xiβ1kl} {Yi −Xiβ1kl}T Qi,1klV−1i,1klXi
]
.
 (2.9)
Proof. We first note that the estimator βˆ1kl satisfies
∑n
i=1X
T
i V
−1
i,1klQi,1kl{Yi − Xiβˆ1kl} =
0. Expanding
∑n
i=1X
T
i V
−1
i,1klQi,1kl{Yi −Xiβˆ1kl} around β1kl using Taylor’s expansion, we
obtain
n
1
2
(
βˆ1kl − β1kl
)
=
[
1
n
n∑
i=1
XTi V
−1
i,1klQi,1klXi
]
−1
n−
1
2
n∑
i=1
XTi V
−1
i,1klQi,1kl {Yi −Xiβ1kl}+ op(1), (2.10)
where op(1) is a term that converges in probability to 0 as n→∞. Note also that[
1
n
n∑
i=1
XTi V
−1
i,1klQi,1klXi
]
p−→ E [XTi V−1i,1klQi,1klXi] = E [XTi V−1i,1klXi] = C (φ,α,β1kl) .
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Therefore, from Equation (2.10), one can write
n
1
2
(
βˆ1kl − β1kl
)
= n−
1
2
n∑
i=1
ψi,1kl + op(1), (2.11)
where ψi,1kl = C
−1(φ,α,β1kl)X
T
i V
−1
i,1klQi,1kl{Yi − Xiβ1kl} is known as the influence func-
tion of the estimator βˆ1kl (where E(ψi,1kl) = 0 and E(ψi,1klψ
T
i,1kl) is positive definite.)
From (2.11), we see that βˆ1kl is an asymptotically linear estimator of β1kl. Applying
the central limit theorem to (2.11), we deduce that n
1
2 (βˆ1kl − β1kl) d−→ MVN(0,Σ), where
Σ = E[ψi,1klψ
T
i,1kl] is given in (2.9).
The asymptotic variance-covariance matrix of βˆ1kl can be estimated by the empirical
estimator
v̂ar
(
βˆ1kl
)
=
1
n
Ê
[
ψi,1klψ
T
i,1kl
]
=
1
n2
n∑
i=1
ψˆi,1klψˆ
T
i,1kl, (2.12)
or by the model-based estimator
v̂ar
(
βˆ1kl
)
=
1
n
[
C−1n (φˆ, αˆ, βˆ1kl)Bn(φˆ, αˆ, βˆ1kl)C
−1
n (φˆ, αˆ, βˆ1kl)
]
, (2.13)
where
ψˆi,1kl = C
−1
n (φˆ, αˆ, βˆ1kl)X
T
i Vˆ
−1
i,1klQi,1kl{Yi −Xiβˆ1kl},
Cn(φˆ, αˆ, βˆ1kl) =
1
n
n∑
i=1
XTi Vˆ
−1
i,1klQi,1klXi,
Bn(φˆ, αˆ, βˆ1kl) =
1
n
n∑
i=1
XTi Vˆ
−1
i,1klQi,1kl{Yi −Xiβˆ1kl}{Yi −Xiβˆ1kl}TQi,1klVˆ−1i,1klXi,
Vˆi,1kl = φˆAˆ
1
2
i,1klR(αˆ)Aˆ
1
2
i,1kl,
Aˆi,1kl = diag(vim(Xi; βˆ1kl),m = 1, . . . ,Mi),
φˆ =
∑n
i=1
∑Mi
m=1 eˆ
2
im∑n
i=1
∑Mi
m=1Qim,1kl − (p+ 2)
, and
eˆim =
√
Qim,1kl(Yim − xTimβˆ1kl).
The specific estimator of α depends on the working correlation structure, R(α) [Liang and
Zeger, 1986]. For example, if corr(Yim(A1BkB
′
l), Yi(m+s)(A1BkB
′
l)) = α
s for s = 0, 1, 2, . . . , (Mi−
m), i.e. R(α) has an autoregressive correlation structure (AR(1)), then αˆ =
∑
n
i=1
∑
m<Mi−1
eˆimeˆi(m+1)
[N∗−(p+2)]φˆ
,
where N∗ =
∑n
i=1[
∑Mi
m=1 I(Qim,1kl > 0)− 1].
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2.4 INFERENCE FROM INCOMPLETE DATA: PRESENCE OF
DROP-OUT
In Section 2.3, we used the IPWGEE method to deal with missing data due to randomization
in the second stage of the therapy. We assumed that there was no drop-out. However, in
longitudinal studies, drop-out is a common phenomenon. The GEE or IPWGEE can provide
valid estimates of parameters as long as drop-outs are missing completely at random, MCAR
[Robins et al., 1995]. If drop-outs depend on observed data (e.g. responses from previous
visits or baseline characteristics), they are not MCAR but missing at random, MAR [Little
and Rubin, 2002]. Therefore, we need to adjust our estimators from Section 2.3 to account
for MAR.
In the presence of drop-outs, the observed data from patient i are
{Wi,∆i,Hi} , k, l = 1, 2, i = 1, . . . , n,
where ∆i = 0 if patient i had dropped out from the study before completion, and ∆i = 1
if otherwise. When ∆i = 1, Hi = {[Ri, Tim1i ], RiZki, (1 − Ri)Z ′li,Yi}. When ∆i = 0, Hi
contains post-baseline information observed prior to drop-out. Thus, when ∆i = 0 and drop-
out occurs at time ti(di+1), Yi is a di × 1 vector, where di < Mi. To account for the data
that are missing due to drop-out, one can extend the idea of inverse-probability-weighting
method described in Section 2.3. We define the probability of a patient having complete data
as pii = P{∆i = 1}. Had this probability been known, each patient who had complete data
would have been weighted by 1/pii to account for the patients who have incomplete data.
We, therefore, modify the m-th diagonal element of the weight matrix Qi,1kl as follows:
Qim,1kl(pii) =
∆i
pii
[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
]
, (2.14)
and the weight matrix Qi,1kl(pii) = diag(Qim,1kl(pii),m = 1, . . . ,Mi). However, pii is unknown
and needs to be estimated. Let pii = Gi(γ) be the postulated model for drop-out process
defined by a set of parameters γ and γˆ be a regular and asymptotically linear (RAL) esti-
mator of γ. The weight in (2.14) is then re-defined by replacing pii by Gi(γˆ); i.e. the m-th
diagonal element of Qi,1kl(γˆ) is {G−1i (γˆ)∆i[η−1k RiZki + ζ−1l (1−Ri)Z ′li]}. Note that we have
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slightly abused the notation to denote this weight matrix by Qi,1kl(γˆ) instead of Qi,1kl(pˆii).
Given a treatment regime A1BkB
′
l, the estimating equation for the IPWGEE is then
n∑
i=1
U∗i (β1kl, γˆ) =
n∑
i=1
XTi V
−1
i,1klQi,1kl(γˆ) {Yi −Xiβ1kl} = 0, (2.15)
where Yi, Xi, and Vi,1kl are defined as in (2.6). Again, as before, the solution of (2.15),
βˆ
∗
1kl, can be obtained through the iterative algorithm.
Lemma 2.4.1. Under SRA in (2.5), and when pii = Gi(γ) is known,
E[Qi,1kl(γ) | Xi,Yi(A1BkB′l)] = IMi.
Proof. Using iterated conditioning,
E [Qim,1kl(γ) | Xi,Yi(A1BkB′l)]
= E
{
E
[
∆i
Gi(γ)
Qim,1kl | ∆i, Ri,Xi,Yi(A1BkB′l)
]}
= E
{
∆i
Gi(γ)
E [Qim,1kl | ∆i, Ri,Xi,Yi(A1BkB′l)]
}
= E
[
∆i
Gi(γ)
× 1
]
= E
{
1
Gi(γ)
E [∆i | Ri,Xi,Yi(A1BkB′l)]
}
=
1
Gi(γ)
× pii = 1, for m = 1, . . . ,Mi.
Lemma 2.4.2. Under CA in (2.4), SRA in (2.5), and when pii = Gi(γ) is correctly specified,
E[U∗i (β1kl,γ)] = 0.
Proof. Under CA in (2.4), Qi,1kl(γ)Yi = Qi,1kl(γ)Yi(A1BkB
′
l). Thus,
E [U∗i (β1kl,γ)] = E
[
XTi V
−1
i,1klQi,1kl(γ) {Yi −Xiβ1kl}
]
= E
[
XTi V
−1
i,1klQi,1kl(γ) {Yi(A1BkB′l)−Xiβ1kl}
]
(by CA in (2.4))
= E
{
E
[
XTi V
−1
i,1klQi,1kl(γ) {Yi(A1BkB′l)−Xiβ1kl} | Xi,Yi(A1BkB′l)
]}
= E
[
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl}
]
(by Lemma 2.4.1)
= E
{
E
[
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl} | Xi
]}
= E
{
XTi V
−1
i,1kl {E [Yi(A1BkB′l) | Xi]−Xiβ1kl}
}
= 0 (by Equation (2.3)).
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Proposition 2.4.1. βˆ
∗
1kl is a consistent estimator of β1kl, provided (1) γˆ is
√
n-consistent,
(2) Gi(γ) is specified correctly, and (3) the probability of having complete data does not
depend on counterfactuals.
Proof. From (1), we can write
√
n(γˆ − γ) = n−1/2∑ni=1ϕi(γ) + op(1), where ϕi(γ) is the
influence function of the estimator γˆ and E[ϕi(γ)] = 0. Since βˆ
∗
1kl satisfies Equation (2.15),
the estimator (βˆ
∗
1kl, γˆ)
T is an M-estimator [Stefanski and Boos, 2002] defined by
n∑
i=1
Ψi(β1kl,γ) =
n∑
i=1
 U∗i (β1kl,γ)ϕi(γ)
 = 0.
The consistency of βˆ
∗
1kl follows from the fact that E[Ψi(β1kl,γ)] = 0 (by Lemma 2.4.2).
Proposition 2.4.2. Under assumptions similar to Proposition 2.4.1, βˆ
∗
1kl is an asymptoti-
cally normally distributed with mean β1kl and variance Σ
∗/n, where
Σ∗ = C∗
−1
(φ,α,β
1kl,γ)B
∗ (φ,α,β
1kl,γ)C
∗
−1
(φ,α,β
1kl,γ) ;
C∗ (φ,α,β
1kl,γ) = E
[
XTi V
−1
i,1klXi
]
;
B∗ (φ,α,β
1kl,γ) = E
[
XTi V
−1
i,1klQi,1kl(γ) {Yi −Xiβ1kl} {Yi −Xiβ1kl}T Qi,1kl(γ)V−1i,1klXi
]
−E
[
XTi V
−1
i,1kl {Yi −Xiβ1kl}ϕTi (γ)
]
D∗
T
(φ,α,β
1kl,γ)
−D∗ (φ,α,β
1kl,γ)E
[
ϕi(γ) {Yi −Xiβ1kl}T V−1i,1klXi
]
+D∗ (φ,α,β
1kl,γ)E
[
ϕi(γ)ϕ
T
i (γ)
]
D∗
T
(φ,α,β
1kl,γ) ;
D∗ (φ,α,β
1kl,γ) =E
[
XTi V
−1
i,1kl {Yi −Xiβ1kl}G−1i (γ) ∂∂γT Gi(γ)
]
.

(2.16)
Proof. We start with the fact that the estimator βˆ
∗
1kl satisfies
∑n
i=1U
∗
i (βˆ1kl, γˆ) = 0. First,
expanding
∑n
i=1U
∗
i (βˆ1kl, γˆ) around β1kl using Taylor’s expansion, we obtain
n
1
2
(
βˆ
∗
1kl − β1kl
)
=
[
− 1
n
n∑
i=1
∂
∂βT1kl
U∗i (β1kl, γˆ)
]
−1
n−
1
2
n∑
i=1
U∗i (β1kl, γˆ) + op(1) (2.17)
Then, applying Taylor’s expansion on (2.17) around γ, it can be rewritten as
n
1
2 (βˆ
∗
1kl − β1kl) =
[
− 1
n
n∑
i=1
∂
∂βT1kl
U∗i (β1kl,γ)
]
−1
n−
1
2
n∑
i=1
U∗i (β1kl,γ)
+

[
− 1
n
n∑
i=1
∂2
∂βT1kl∂γ
T
U∗i (β1kl,γ)
]
−1
1
n
n∑
i=1
U∗i (β1kl,γ)
+
[
− 1
n
n∑
i=1
∂
∂βT1kl
U∗i (β1kl,γ)
]
−1
1
n
n∑
i=1
∂
∂γT
U∗i (β1kl,γ)
× n 12 (γˆ − γ) + op(1). (2.18)
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Note the convergence of the following quantities in (2.18) as n→∞:
− 1
n
n∑
i=1
∂
∂βT1kl
U∗i (β1kl,γ)
p−→ E [XTi V−1i,1klXi] = C∗ (φ,α,β1kl,γ) , (2.19)
1
n
n∑
i=1
U∗i (β1kl,γ)
p−→ 0 (by Lemma 2.4.2), and (2.20)
1
n
n∑
i=1
∂
∂γT
U∗i (β1kl,γ)
p−→ −E
[
XTi V
−1
i,1kl {Yi −Xiβ1kl}G−1i (γ)
∂
∂γT
Gi(γ)
]
. (2.21)
Using (2.19) – (2.21), we can write (2.18) as n1/2(βˆ
∗
1kl − β1kl) = n−1/2
∑n
i=1ψ
∗
i,1kl + op(1),
where ψ∗i,1kl is the influence function of the estimator βˆ
∗
1kl and can be expressed as
C∗
−1
(φ,α,β1kl,γ)
{
XTi V
−1
i,1klQi,1kl(γ) {Yi −Xiβ1kl} −D∗ (φ,α,β1kl,γ)ϕi(γ)
}
, (2.22)
where D∗(φ,α,β1kl,γ) = E[X
T
i V
−1
i,1kl{Yi −Xiβ1kl}G−1i (γ) ∂∂γT Gi(γ)]. By central limit the-
orem, we can deduce that n1/2(βˆ
∗
1kl − β1kl) d−→ MVN(0,Σ∗), where Σ∗ = E[ψ∗i,1klψ∗
T
i,1kl] and
is given in (2.16).
The asymptotic variance-covariance matrix of βˆ
∗
1kl can be estimated by the empirical
estimator
v̂ar
(
βˆ
∗
1kl
)
=
1
n
Ê
[
ψ∗i,1klψ
∗
T
i,1kl
]
=
1
n2
n∑
i=1
ψˆ
∗
i,1klψˆ
∗
T
i,1kl, (2.23)
or by the model-based estimator
v̂ar
(
βˆ
∗
1kl
)
=
1
n
E
[
C∗
−1
n
(
φˆ, αˆ, βˆ
∗
1kl, γˆ
)
B∗n
(
φˆ, αˆ, βˆ
∗
1kl, γˆ
)
C∗
−1
n
(
φˆ, αˆ, βˆ
∗
1kl, γˆ
)]
, (2.24)
where
ψˆ
∗
i,1kl = C
∗
−1
n (φˆ, αˆ, βˆ
∗
1kl, γˆ){XTi Vˆ−1i,1klQi,1kl(γˆ)[Yi −Xiβˆ
∗
1kl]−D∗n(φˆ, αˆ, βˆ
∗
1kl, γˆ)ϕi(γˆ)},
C∗n(φˆ, αˆ, βˆ
∗
1kl, γˆ) =
1
n
n∑
i=1
XTi Vˆ
−1
i,1klQi,1kl(γˆ)Xi,
D∗n(φˆ, αˆ, βˆ
∗
1kl, γˆ) =
1
n
n∑
i=1
[XTi Vˆ
−1
i,1klQi,1kl(γˆ){Yi −Xiβˆ
∗
1kl}G−1i (γˆ)G˙i(γˆ)],
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and
B∗n
(
φˆ, αˆ, βˆ
∗
1kl, γˆ
)
=
1
n
n∑
i=1
[
XTi Vˆ
−1
i,1klQi,1kl(γˆ)
{
Yi −Xiβˆ∗1kl
}{
Yi −Xiβˆ∗1kl
}T
Qi,1kl(γˆ)Vˆ
−1
i,1klXi
]
−
{
1
n
n∑
i=1
[
XTi Vˆ
−1
i,1klQi,1kl(γˆ)
{
Yi −Xiβˆ∗1kl
}
ϕTi (γˆ)
]}
×D∗n
(
φˆ, αˆ, βˆ
∗
T
1kl, γˆ
)
−D∗n
(
φˆ, αˆ, βˆ
∗
1kl, γˆ
)
×
{
1
n
n∑
i=1
[
ϕi(γˆ)
{
Yi −Xiβˆ∗1kl
}T
Qi,1kl(γˆ)Vˆ
−1
i,1klXi
]}
+D∗n
(
φˆ, αˆ, βˆ
∗
1kl, γˆ
)
×
{
1
n
n∑
i=1
[
ϕi(γˆ)ϕ
T
i (γˆ)
]}×D∗Tn (φˆ, αˆ, βˆ∗1kl, γˆ) .
The estimators of φ, α, Vi,1kl, and Ai,1kl are obtained by replacing βˆ1kl with βˆ
∗
1kl and Qi,1kl
with Qi,1kl(γˆ) in (2.12) and (2.13).
2.5 COMPARISON AMONG TREATMENT REGIMES
To compare the effects of various treatment regimes, contrasts of target regime effects can be
constructed and tested via Wald test. Since a patient can belong to more than one regime,
the estimators of treatment effects among regimes will be correlated. In such situations, the
covariance between estimators needs to be estimated. In the case of four treatment regimes,
A1BkB
′
l for k, l ∈ {1, 2}, one can consider six pairwise comparisons of the estimators of
these four treatment regimes. Among these six pairs of the estimators, the covariance of
(βˆ
∗
111, βˆ
∗
122) will be zero, since βˆ
∗
111 and βˆ
∗
122 are estimated using data from two different
subgroups of patients. For the same reason, the covariance of (βˆ
∗
112, βˆ
∗
121) will also be zero.
However, the estimators βˆ
∗
111 and βˆ
∗
112 are correlated, since both estimators used the same
information from those patients who received A1 and followed with B1 after responding to
A1. Hence, the covariance of (βˆ
∗
111, βˆ
∗
112) needs to be estimated. Similarly, we will have to
estimate the covariances for the pairs (βˆ
∗
111, βˆ
∗
121), (βˆ
∗
112, βˆ
∗
122), and (βˆ
∗
121, βˆ
∗
122).
To estimate the covariance between two correlated estimators, we use the fact that the
large-sample covariance between two estimators can be obtained through the expectation
of the product of their influence functions. We will demonstrate covariance computation
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for the pair of estimators βˆ
∗
111 and βˆ
∗
112. Similar computation follows for other correlated
pairs. The covariance of βˆ
∗
111 and βˆ
∗
112 is given by n
−1E[ψ∗i,111ψ
∗
T
i,112], where ψ
∗
i,111 and ψ
∗
T
i,112
are the influence functions of estimators βˆ
∗
111 and βˆ
∗
112, which are obtained from Equation
(2.22). Therefore, one can estimate the covariance of βˆ
∗
111 and βˆ
∗
112 in a manner similar to
the estimation of variance-covariance matrix through Equation (2.23) or (2.24).
To test the effects of treatment regimesA1BkB
′
l for k, l ∈ {1, 2}, β = [βT111,βT112,βT121,βT122]T
via Wald test, one can establish the null hypothesis of Aβ = 0, where each β1kl is a
(p + 2)-dimensional vector and A is a matrix with [4(p + 2)] columns such that rank(A) <
[4(p + 2)]. The test statistic will be T = (Aβˆ)T (AΣˆAT )−1(Aβˆ) ∼ χ2rank(A), where βˆ =
[βˆ
∗
T
111, βˆ
∗
T
112, βˆ
∗
T
121, βˆ
∗
T
122]
T and Σˆ is the estimated covariance matrix of βˆ. Each element of Σˆ
can be obtained by calculating the covariances of all pairs of estimators.
2.6 SIMULATION STUDY
To evaluate the performance of the estimators in small samples, we conducted several sim-
ulation studies. We simulated data from a population which has similar design to the
REVAMP study. Each patient will have repeated measurements at each visit so that
ti = (0, 2, 4, 6, 8, 10, 12)
T for patient i. We considered one initial treatment A1, two sec-
ond stage treatments, B1 and B2, for responders, and two second stage treatments, B
′
1 and
B′2, for non-responders. All patients received initial treatment A1 at ti1 = 0. For each pa-
tient i, we generated counterfactual random variables listed in (2.1). At ti3 = 4 and ti4 = 6,
patients were assessed to see if they had responded to the initial treatment A1. Thus, the
index of the time of response in this case is m1i = 3 or 4. The response status, Ri, was drawn
from a Bernoulli(θ) distribution. We assume that of these responders, 100× θ1% responded
at time ti3 and the rest at time ti4. Thus each responder was assigned randomly to respond
at time ti3 with probability θ1. We considered two sets of parameters, (θ, θ1) = (0.5, 0.25)
and (0.3, 0.15) meaning 50% (30%) of the patients would respond of which 25% (15%) would
respond at time ti3 and the rest at time ti4. We also generated a baseline covariate, age,
which follows a normal distribution with mean µage = 45 and standard deviation σage = 11.
22
For each patient i, counterfactual outcome vectors Yi(A1), Yi(A1B1), Yi(A1B2), Yi(A2B1),
and Yi(A2B
′
2), were generated from the following multivariate noraml distributions (MVN):
Yi(A1) ∼ MVNm1i((θ1,A1 + θ2,A1 × agei)× 1m1i + θ3,A1 × t0i,Σ0),
Yi(A1B1) ∼ MVN7−m1i((θ1,A1B1 + θ2,A1B1 × agei)× 1(7−m1i) + θ3,A1B1 × t1i,Σ1),
Yi(A1B2) ∼ MVN7−m1i((θ1,A1B2 + θ2,A1B2 × agei)× 1(7−m1i) + θ3,A1B2 × t1i,Σ1),
Yi(A1B
′
1) ∼ MVN7−m1i((θ1,A1B′1 + θ2,A1B′1 × agei)× 1(7−m1i) + θ3,A1B′1 × t1i,Σ1),
and Yi(A1B
′
2) ∼ MVN7−m1i((θ1,A1B′2 + θ2,A1B′2 × agei)× 1(7−m1i) + θ3,A1B′2 × t1i,Σ1),
wherem1i equals to either 3 or 4; t0i is am1i×1 vector which indicates weeks of measurements
in the first stage and t1i is a (7−m1i)×1 vector which indicates weeks of measurements in the
second stage; Σ0(σ0, ρ0) is am1i×m1i covariance matrix defined by standard deviation σ0 and
autoregressive correlation ρ0; Σ1(σ1, ρ1) is a (7−m1i)× (7−m1i) covariance matrix defined
by standard deviation σ1 and autoregressive correlation ρ1. The values of σ0, σ1, ρ0, and ρ1
were set to be 5, 3, 0.8, and 0.8, respectively. For each patient i, the m-th element of the
counterfactual outcome under a treatment regime A1BkB
′
l for k, l = 1, 2 and m = 1, 2, . . . , 7
is generated using Equation (2.2). The estimation of parameters β1kl = (β0,1kl, β1,1kl, β2,1kl)
T
in Equation (2.3) of the model E[Yim(A1BkB
′
l) | xim] = xTimβ1kl was the main focus in this
article, where xim = [1, tim, agei]
T .
We considered the following parameter values for each counterfactual vector: θ1,A1= 25,
θ2,A1= 0.5, θ3,A1= -0.5, θ1,A1B1= 27, θ2,A1B1= 0.6, θ3,A1B1= -1.5, θ1,A1B2= 38, θ2,A1B2= 0.4,
θ3,A1B2= -2, θ1,A1B′1= 36, θ2,A1B′1= 0.7, θ3,A1B′1= -3, θ1,A1B′2= 68, θ2,A1B′2= 0.3, and θ3,A1B′2=
-5. For this population, the true parameter values were βT111 = [23.09,−1.13, 0.57], βT112 =
[27.94,−1.53, 0.48], βT121 = [25.45,−1.30, 0.52], and βT122 = [30.38,−1.69, 0.43] for 50% re-
sponse, and βT111 = [22.88,−1.20, 0.58], βT112 = [29.65,−1.77, 0.45], βT121 = [24.28,−1.31, 0.55],
and βT122 = [31.10,−1.86, 0.42] for 30% response.
We simulated 2000 Monte Carlo samples of sizes 250 and 400 observations from the
populations described above with the following characteristics. For responders (i.e. Ri = 1),
the assignment indicator, Z1i, for treatment B1 was drawn from a Bernoulli distribution with
probability η1; the assignment indicator for treatment B2 was defined as Z2i = 1− Z1i. For
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non-responders (i.e. Ri = 0), the assignment indicator, Z
′
1i, for treatment B
′
1 was drawn
from a Bernoulli distribution with probability ζ1; the assignment indicator for treatment B
′
2
was defined as Z ′2i = 1 − Z ′1i. We defined the observed outcome for patient i at tim as in
Equation (2.4).
Additionally, a number of patients were allowed to drop out for the purpose of illustration
based on the following logistic regression model: pii = Gi(γ) = Pr(∆i = 1 | γ, age, Yi1) =
[1 + exp(−γ0 − γ1 × agei − γ2 × Yi1)]−1, where γ = [γ0, γ1, γ2]T ; Yi1 is the outcome at
ti1 = 0 for patient i. Choices of values of parameters γ = [5.4,−0.02,−0.07]T and γ =
[5.1,−0.03,−0.08]T gave us approximate drop-out rates of 25% and 50%, respectively. For
sample sizes of 250 and 400 and response rates of 50% and 30%, we considered the following
drop-out rates and analysis strategies: (1) no drop-out with weighting for randomization (Q);
(2) 25% drop-out rate with weighting for randomization only (Q); (3) 25% drop-out rate
with weighting for randomization and drop-out (Q(γ)); (4) 50% drop-out rate with weighting
for randomization only (Q); (5) 50% drop-out rate with weighting for randomization and
drop-out (Q(γ)).
Table 2.1 shows the simulation results of estimation for samples of size 250. When the
missing was due to randomization only (i.e. no drop-out), the IPWGEE estimators with
Q as weight matrix were approximately unbiased for all regimes regardless of the response
rates. The maximum relative bias observed was 0.8%. The estimated standard deviations
of the estimators were consistent with the Monte Carlo standard deviations. The coverage
probabilities for the 95% Wald confidence intervals for the parameters were between 92.4%
and 95.7%. For the 25% drop-out rate, the estimators were biased when the drop-out were
ignored (i.e. used Q as weight matrix in the IPWGEE.) The relative biases ranged from
0.8 to 3.4%. When the analysis accounted for drop-outs using Q(γ) as weight matrix in
the IPWGEE, the estimators were approximately unbiased. For example, the estimator
weighted by Q for regime A1B2B
′
2 with 30% response rate had relative bias 3.2%, however,
the estimator weighted by Q(γ) for the same had near zero bias. The estimated standard
deviations of estimators weighted by Q(γ) were consistent with corresponding Monte Carlo
standard deviations. The Wald confidence intervals achieved coverage close to their nominal
confidence levels. When the drop-out rate was raised from 25% to 50%, similar results were
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observed. The estimators weighted byQ(γ) remained approximately unbiased for all regimes
under both 50% and 30% response rates. Standard errors of estimators were slightly higher
for higher drop-out rate.
For n = 400 (shown in Table 2.2), the estimators with proper weighting were approxi-
mately unbiased regardless of response and drop-out rates. The standard errors of estimators
were, as expected, smaller than those for n = 250. The coverage probabilities for the 95%
Wald confidence intervals ranged from 92.4% to 95.2%.
2.7 ANALYSIS OF THE REVAMP DATA
A total of 808 patients with chronic forms of major depressive disorders were enrolled in the
REVAMP study [Trivedi et al., 2008]. Patients were evaluated in two 12-week stages for
a maximum of 24 weeks. In the first stage, patients were treated with one of four antide-
pressants: Sertaline (SERT), Escitalopram (EcCIT), Bupropion (BUP-SR), and Venlafaxine
(VLF-XR). The choice of antidepressants was based on the algorithm using information on
pharmacotherapy treatment history (see Trivedi et al., 2008 for more details.) During weeks
8 through 12 in the first stage, each patient was evaluated to assess the response. Patients
with full response continued their antidepressant in the second stage. Patients who did
not meet the criteria of full response were randomly assigned to three groups: Cognitive
Behavioral Analysis System of Psychotherapy (CBASP) plus medication, Brief Supportive
Psychotherapy (BSP) plus medication, or Medication alone (MED). The randomization was
done with unequal probabilities of 0.4, 0.4, and 0.2, respectively, to CBASP, BSP, and MED.
For the purpose of illustration, we considered only patients treated with SERT in this arti-
cle. Hence, we were interested in comparing three treatment regimes: (1) treat with SERT,
continue SERT if respond, otherwise add CBASP to SERT; (2) treat with SERT, continue
SERT if respond, otherwise add BSP to SERT; and (3) treat with SERT, continue SERT
if respond, otherwise add MED to SERT. These three regimes are denoted by SSC, SSB,
and SSM, respectively. The response to therapy was measured by the 24-item Hamilton
Rating Scale for Depression (HRSD) score at each visit. Figure 2.2 shows the design and
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patient flow of 618 patients in the REVAMP study who received SERT. The responses of
136 patients could not be assessed since they dropped out from the study in the first stage.
For 482 patients entering the second stage, about 65% of patients completed the study. To
show a snapshot of the data, we have presented the HRSD scores of eight selected patients
in Figure 2.3. The left panel of Figure 2.3 represents the HRSD scores for patients who had
their response status confirmed at various time points and went on to complete the study.
The right panel of Figure 2.3 represents the HRSD scores for patients who dropped out from
the study (their response statuses may or may not have been confirmed.) Figure 2.3 illus-
trates how information collected in a two-stage longitudinal study can vary across patients
due to response and drop-out. Because of the presence of drop-outs, we applied the IP-
WGEE method described in Section 2.4 to estimate the effects of three depression treatment
regimes in the REVAMP study. The effect of the r-th treatment regime was formulated as
the coefficients βr in the marginal mean model:
E [HRSDim(r) | xim] = xTimβ
= β0,r + β1,r × tim + β2,r × agei + β3,r × empi + β4,r × agei × tim,
where r ∈ {SSC, SSB, SSM}; empi=1 if employed and empi=0 otherwise. To account for
incompleteness through the IPWGEE, the probability of having complete data for patient
i, pii = P{∆i = 1} = Gi(γ), was estimated from the data. Table 2.3 shows the distribu-
tions of drop-outs across baseline covariates. In univariate analysis using chi-square test (or
Fisher’s exact test) with level of 0.05, Caucasian race, higher education, and older age were
significantly associated with having complete data. Based on the results in Table 2.3 and
model selection strategy, a logistic model for pii was postulated with covariates including
Caucasian race, employment status, education level, age, and the baseline observed HRSD
score. Specifically,
pˆii = Gi (γˆ)
= [1 + exp(−γˆ0 − γˆ1 × racei − γˆ2 × empi − γˆ3 × edui − γˆ4 × agei − γˆ5 × HRSDi1)]−1,
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where racei=1 if Caucasian and racei=0 if otherwise; empi=1 if employed and empi=0 if
otherwise; edui=1 if education higher than high school and edui=0 if otherwise; HRSDi1 is
the observed HRSD score at baseline.
The results of the REVAMP data analysis are shown in Table 2.4. Controlling for the
baseline employment status, for a patient of age 43 years, the treatment regime SSB will have
the highest reduction of 0.741 per week in the HRSD scores from baseline, followed by the
treatment regime SSC (0.707/week) and then by the treatment regime SSM (0.702/week).
While the effect of each treatment regime was statistically significant (p<0.001), the mag-
nitude of the effect was similar across three regimes. In Table 2.5, a Wald Chi-square test
comparing the effects of treatment regimes (H0 : β1,SSC+β4,SSC×43 = β1,SSB+β4,SSB×43 =
β1,SSM + β4,SSM × 43) with 2 degrees of freedom resulted in a p-value of 0.842, indicating
that there was no evidence that the effects of these three treatment regimes were significantly
different from each other.
2.8 DISCUSSION
In a two-stage longitudinal study, such as the one presented here, drop-out is a common
phenomenon. If the drop-out occurs prior to the second randomization, a patient’s response
status will be unknown. Additionally, in the second stage of the study, patients random-
ized to one treatment can not receive other competing treatments, hence the fundamental
problem of causal inference [Holland, 1986] applies. We have used the inverse-probability-
weighted generalized estimating equations (IPWGEE) method (Robins et al., 1995) to take
into account the missing data due to randomization and drop-out. The weights are formed
by inversely weighting the probability of randomization to the treatment dictated by the
regime and the probability of having complete data. The probability of having complete
data is estimated through a logit model. We showed that the IPWGEE estimators are con-
sistent and asymptotically normal. We have provided evidence of the bias incurred when
appropriate weighting is not applied. We also showed how to compare treatment regimes via
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Wald test, which required computation of covariance between two estimated regime effects.
We have demonstrated our methods using a dataset from a depression study.
Our methods account for missing data due to randomization and drop-out. However,
they ignore the time to response and the time to drop-out in the second stage. It is possible
to increase precision of the estimators by incorporating these two phenomenons into the
estimation process. We will present this generalization in Chapter 3.
2.9 FIGURES AND TABLES
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Figure 2.1: A study with two-stage design.
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Figure 2.2: Patient flow in the REVAMP study.
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Figure 2.3: The HRSD scores of eight selected patients in the REVAMP study.
Patients A, B, C, and D completed the study while patients E, F, G, and H did not. Patients
A and B are non-responders whose response status was confirmed at weeks 10 and 8, respec-
tively. Patients C and D are responders whose response status was confirmed at weeks 12
and 8, respectively. Patient E dropped out at week 4 without response information. Patient
F dropped out at week 20 after failing to respond by week 12. Patients G and H dropped out
at weeks 16 and 20 after responding to initial treatment at weeks 8 and 12, respectively. The
solid lines represent responders, the dashed lines represent non-responders, and the dotted
line represents patient who dropped out before the randomization and his/her response sta-
tus could not be ascertained. The closed circles show when the HRSD scores were measured,
the open squares show when the response status was confirmed.
29
Table 2.1: Simulation results of βˆ1,1kl based on 2000 Monte Carlo (MC) samples of size 250. EST is MC mean of
estimates, SE is MC mean of estimated standard errors, MCSE is standard error of MC estimates, and CP is empirical coverage
probability.
Drop-out Response Regime True EST (SE) MCSE CP% EST (SE) MCSE CP%
Rate Rate Value
Weighted by Q Weighted by Q(γ)
0% 50% A1B1B
′
1 -1.13 -1.13 (0.050) 0.050 95.7 Not applicable
A1B1B
′
2 -1.53 -1.53 (0.070) 0.075 94.1 Not applicable
A1B2B
′
1 -1.30 -1.30 (0.047) 0.049 92.8 Not applicable
A1B2B
′
2 -1.69 -1.70 (0.060) 0.065 92.4 Not applicable
30% A1B1B
′
1 -1.20 -1.20 (0.050) 0.051 93.8 Not applicable
A1B1B
′
2 -1.77 -1.76 (0.067) 0.069 94.3 Not applicable
A1B2B
′
1 -1.31 -1.30 (0.047) 0.047 95.2 Not applicable
A1B2B
′
2 -1.86 -1.86 (0.058) 0.060 94.6 Not applicable
25% 50% A1B1B
′
1 -1.13 -1.12 (0.058) 0.060 92.6 -1.13 (0.056) 0.054 96.2
A1B1B
′
2 -1.53 -1.49 (0.079) 0.084 89.9 -1.53 (0.082) 0.088 95.9
A1B2B
′
1 -1.30 -1.27 (0.054) 0.057 90.6 -1.31 (0.053) 0.056 92.1
A1B2B
′
2 -1.69 -1.64 (0.068) 0.072 86.1 -1.71 (0.068) 0.070 94.4
30% A1B1B
′
1 -1.20 -1.19 (0.058) 0.058 93.9 -1.21 (0.056) 0.057 94.0
A1B1B
′
2 -1.77 -1.71 (0.075) 0.079 87.4 -1.76 (0.079) 0.084 93.4
A1B2B
′
1 -1.31 -1.28 (0.055) 0.056 91.7 -1.30 (0.054) 0.053 94.3
A1B2B
′
2 -1.86 -1.80 (0.066) 0.069 82.2 -1.86 (0.067) 0.072 93.4
50% 50% A1B1B
′
1 -1.13 -1.10 (0.071) 0.070 91.8 -1.13 (0.069) 0.076 92.2
A1B1B
′
2 -1.53 -1.44 (0.093) 0.093 86.2 -1.53 (0.110) 0.117 92.4
A1B2B
′
1 -1.30 -1.24 (0.067) 0.072 83.4 -1.29 (0.068) 0.079 93.1
A1B2B
′
2 -1.69 -1.58 (0.081) 0.087 66.8 -1.69 (0.090) 0.100 92.6
30% A1B1B
′
1 -1.20 -1.18 (0.072) 0.073 93.4 -1.20 (0.070) 0.075 93.5
A1B1B
′
2 -1.77 -1.65 (0.090) 0.091 75.3 -1.76 (0.105) 0.110 92.6
A1B2B
′
1 -1.31 -1.26 (0.068) 0.068 90.1 -1.30 (0.068) 0.070 94.0
A1B2B
′
2 -1.86 -1.73 (0.080) 0.083 58.2 -1.86 (0.088) 0.095 92.8
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Table 2.2: Simulation results of βˆ1,1kl based on 2000 Monte Carlo (MC) samples of size 400. EST is MC mean of
estimates, SE is MC mean of estimated standard errors, MCSE is standard error of MC estimates, and CP is empirical coverage
probability.
Drop-out Response Regime True EST (SE) MCSE CP% EST (SE) MCSE CP%
Rate Rate Value
Weighted by Q Weighted by Q(γ)
0% 50% A1B1B
′
1 -1.13 -1.13 (0.042) 0.042 95.5 Not applicable
A1B1B
′
2 -1.53 -1.53 (0.060) 0.062 94.4 Not applicable
A1B2B
′
1 -1.30 -1.30 (0.040) 0.041 93.9 Not applicable
A1B2B
′
2 -1.69 -1.70 (0.051) 0.053 94.7 Not applicable
30% A1B1B
′
1 -1.20 -1.20 (0.039) 0.040 94.5 Not applicable
A1B1B
′
2 -1.77 -1.76 (0.053) 0.055 94.1 Not applicable
A1B2B
′
1 -1.31 -1.30 (0.038) 0.039 93.1 Not applicable
A1B2B
′
2 -1.86 -1.86 (0.046) 0.048 94.6 Not applicable
25% 50% A1B1B
′
1 -1.13 -1.12 (0.045) 0.046 94.2 -1.13 (0.044) 0.045 92.4
A1B1B
′
2 -1.53 -1.49 (0.062) 0.064 89.0 -1.53 (0.065) 0.065 95.2
A1B2B
′
1 -1.30 -1.27 (0.043) 0.042 90.0 -1.30 (0.042) 0.044 94.5
A1B2B
′
2 -1.69 -1.64 (0.054) 0.054 80.7 -1.69 (0.055) 0.057 94.6
30% A1B1B
′
1 -1.20 -1.19 (0.046) 0.046 94.3 -1.20 (0.044) 0.044 94.2
A1B1B
′
2 -1.77 -1.71 (0.060) 0.062 83.0 -1.76 (0.063) 0.064 94.6
A1B2B
′
1 -1.31 -1.29 (0.043) 0.044 91.4 -1.30 (0.042) 0.042 94.6
A1B2B
′
2 -1.86 -1.80 (0.052) 0.056 76.6 -1.86 (0.053) 0.053 95.0
50% 50% A1B1B
′
1 -1.13 -1.11 (0.056) 0.057 92.5 -1.13 (0.055) 0.058 93.5
A1B1B
′
2 -1.53 -1.44 (0.074) 0.074 77.6 -1.53 (0.088) 0.093 93.6
A1B2B
′
1 -1.30 -1.24 (0.052) 0.056 79.1 -1.30 (0.054) 0.059 93.4
A1B2B
′
2 -1.69 -1.57 (0.065) 0.066 48.8 -1.70 (0.073) 0.076 93.9
30% A1B1B
′
1 -1.20 -1.18 (0.056) 0.058 93.1 -1.20 (0.056) 0.056 94.8
A1B1B
′
2 -1.77 -1.65 (0.071) 0.072 60.8 -1.76 (0.084) 0.089 94.5
A1B2B
′
1 -1.31 -1.27 (0.053) 0.054 87.8 -1.30 (0.054) 0.056 93.3
A1B2B
′
2 -1.86 -1.73 (0.063) 0.063 39.7 -1.86 (0.070) 0.073 93.8
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Table 2.3: Drop-out rates by baseline characteristics.
Characteristics Complete Incomplete p-value
(n=400) (n=218)
Categorical: No. (%)
Sex
Male 185 (66.1) 95 (33.9) 0.52
Female 215 (63.6) 123 (36.4)
Caucasian Race
Yes 344 (66.9) 170 (33.1) 0.01
No 56 (53.9) 48 (46.2)
Hispanic ethnicity
Yes 33 (58.9) 23 (41.1) 0.34
No 362 (65.3) 192 (34.7)
Missing, No. 5 3
Employment
Employed 255 (66.9) 126 (33.1) 0.12
Unemployed 141 (60.8) 91 (39.2)
Missing, No. 4 1
Education
≤ High school 139 (53.9) 119 (46.1) <0.01
> High school 241 (71.5) 96 (28.5)
Missing, No. 20 3
Marital status
Married 158 (68.7) 72 (31.3) 0.10
Not married 238 (62.1) 145 (37.9)
Missing, No. 4 1
Continuous: mean (s.d.)
Age, year
Mean (SD) 45.6 (12.2) 39.4 (12.0) <0.01
Missing, No. 1 0
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Table 2.4: Estimated effects of treatment regimes in the REVAMP study.
Regime Effect Estimated Standard p-value
Parameter Error
SSC 1 Intercept 26.817 2.218 <0.001
Time -0.836 0.137 <0.001
Age -0.008 0.041 0.842
Employment -1.056 1.249 0.398
Time×Age 0.003 0.003 0.338
SSB 2 Intercept 25.380 1.659 <0.001
Time -0.913 0.076 <0.001
Age 0.016 0.032 0.632
Employment -2.244 0.835 0.007
Time×Age 0.004 0.002 0.013
SSM 3 Intercept 29.268 2.821 <0.001
Time -0.711 0.116 <0.001
Age -0.065 0.048 0.175
Employment -3.135 1.423 0.028
Time×Age 0.0002 0.003 0.939
1 Treat with SERT, continue SERT if respond, otherwise add CBASP to SERT
2 Treat with SERT, continue SERT if respond, otherwise add BSP to SERT
3 Treat with SERT, continue SERT if respond, otherwise add MED to SERT
Table 2.5: Comparisons of the estimated effects of treatment regimes on the HRSD
score for a patient of 43 years controlling for baseline employment status in the
REVAMP study.
Regime Estimated Effect χ22 p-value
SSC 1 -0.836 + 0.003×43 0.345 0.842
SSB 2 -0.913 + 0.004×43
SSM 3 -0.711 + 0.0002×43
1 Treat with SERT, continue SERT if respond, otherwise add CBASP to SERT
2 Treat with SERT, continue SERT if respond, otherwise add BSP to SERT
3 Treat with SERT, continue SERT if respond, otherwise add MED to SERT
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3.0 WEIGHTED ESTIMATING EQUATIONS IN TWO-STAGE
LONGITUDINAL STUDIES IN THE PRESENCE OF TIME-DEPENDENT
MISSING
3.1 INTRODUCTION
Pharmacotherapies and psychotherapies are commonly used to alleviate mood disorders in
patients with chronic forms of major depression [Keller et al., 2000, Cuijpers et al., 2010].
The effect of using a single treatment in the management of depression had been investigated
rigorously in medical research. The most common pharmacotherapies include classes of
selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors
(SNRIs), tetracyclic antidepressants (TeCAs), and dopamine reuptake inhibitors (DRIs).
The psychotherapies include cognitive behavioral analysis system of psychotherapy (CBASP)
and brief supportive psychotherapy (BSP). Despite the apparent effectiveness of treatments
for major depressive disorders, nearly 50% of the patients with chronic forms of major
depressive disorders fail to respond to the first line of pharmacotherapies or psychotherapies
[Kocsis et al., 2009]. Studies have shown that the augmentation with psychotherapy when
pharmacotherapy alone was ineffective seemed to be an effective alternative to the treatment
of chronically depressed patients [Cuijpers et al., 2009].
In an attempt to investigate the effect of sequence of pharmacotherapy and psychother-
apy in the treatment of patients with chronic depression, the Research Evaluating the Value
of Augmenting Medication with Psychotherapy (REVAMP) study [Trivedi et al., 2008] en-
rolled a total of 808 patients to determine the role of adjunctive psychotherapy in chronically
depressed patients who had less than complete response to an initial medication. The study
consisted of two stages of maximum 12-week duration, for a maximum treatment duration of
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24 weeks. In the first stage, patients were assigned one of four treatments of antidepressants
by the REVAMP physicians based on the algorithm using information on pharmacotherapy
treatment history. These antidepressants were Sertaline (SERT), Escitalopram (EcCIT),
Bupropion (BUP-SR), and Venlafaxine (VLF-XR). During weeks 8 through 12, patients
whose depressive symptoms did not meet certain criteria were declared as non-responders. In
the second stage, the non-responders were randomly assigned to three groups in a 2:2:1 ratio.
The first two groups were to have Cognitive Behavioral Analysis System of Psychotherapy
(CBASP) or Brief Supportive Psychotherapy (BSP) added to their pharmacotherapy and
the third group was to receive medication alone (MED). Patients who were declared respon-
ders, continued receiving their antidepressant from the first stage. Throughout the study,
a patient’s 24-item Hamilton Rating Scale for Depression (HRSD) scores [Hamilton, 1960]
were collected at each visit. The higher the HRSD scores, the worse is the symptoms of
depression. The goal of the REVAMP study was to find the most beneficial combination of
pharmacotherapy and psychotherapy for each chronically depressed patient.
In many depression studies, multiple stages of sequential treatments had been suggested
as an alternative treatment strategy to a single episode of treatment for chronically depressive
disorders [Nierenberg et al., 2003, Thase et al., 2007]. For example, a strategy for treating
patients with chronically depressive disorders could be: treat with the antidepressant based
on the pre-determined treatment algorithm in the first stage, continue the same if responds
by 12 weeks, else add CBASP with the medication. This strategy in which the treatment in
the second stage depends on a patient’s intermediate response is called adaptive treatment
strategy [Lavori and Dawson, 2000] or dynamic treatment regime [Murphy, 2003]. When
physicians make decisions about treatments for patients with chronically depressive disorders,
their decisions follow the logic of adaptive strategy or dynamic regime. However, most of
the conventional statistical analysis focuses only on the comparisons among fixed treatments
or non-dynamic regime. To estimate the effects of depression treatment regimes in two-
stage longitudinal studies, adjustments to the conventional statistical analyses are needed
[Lunceford et al., 2002].
Estimation of time-varying treatment effects has been discussed in the literature by
many authors [Herna´n et al., 2000, Murphy et al., 2001, Ko et al., 2003, Bodnar et al., 2004,
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VanderWeele, 2009]. An estimation method for the mean response that would have been
observed if the entire population followed a dynamic regime, where the available data were
observational [Murphy et al., 2001]. A marginal structural model was used to estimate the
causal effects of time-dependent treatments by modeling the counterfactual random variables
[Herna´n et al., 2000, Ko et al., 2003, Bodnar et al., 2004]. A marginal structural model
with inverse probability treatment weighting was used to estimate the controlled direct and
indirect effects [VanderWeele, 2009].
Missing data is common in almost all longitudinal studies. For example, in the two-stage
longitudinal REVAMP study, missing data could occur in two ways. First, by study design,
patients are randomized to three groups in the second stage, and hence patients receiving one
psychotherapy will have missing (counterfactual) data on the other groups. Second, patients
can drop out at any time during the study period. Under the framework of the generalized
estimating equations [Liang and Zeger, 1986], the inverse-probability-weighted methodology
could correct the bias caused by ignoring missing data [Robins and Rotnitsky, 1992, Robins
et al., 1995]. With the knowledge of time to response and time to drop-out, one could
also improve upon the analysis by including more observations in the analysis compared to
complete case analysis, which may intuitively increase the efficiency of the estimators.
In this chapter, we demonstrate an application of the inverse-probability-weighted gener-
alized estimating equations to a two-stage longitudinal depression study in order to estimate
the effects of depression treatment regimes in the presence of drop-out. We constructed the
weights which allow us to use the partial information from patients who belonged to treat-
ment regimes other than the targeted one and who dropped out from the study. The outline
of this paper is as follows. We introduce notation, model, and assumptions in Section 3.2.
In Section 3.3, we show how to construct the weights and draw inference from the observed
data. In Section 3.4, we evaluate the asymptotic properties of the proposed methods through
simulations. In Section 3.5, we demonstrate these methods through an application to the
REVAMP dataset. We wrap up with a discussion in Section 3.6. The figures and tables are
listed in Section 3.7.
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3.2 MODEL FRAMEWORK AND NOTATION
Let us consider a study with two-stage setting that mimics the design of the REVAMP
study. For each patient i (i = 1, . . . , n), there are J treatments available in the first stage,
Aj, where j ∈ {1, . . . , J}. Patients responding to Aj are assigned to treatment Bk, where
k ∈ {1, . . . , K} and patients failing to respond to Aj are assigned to treatment B′l, where
l ∈ {1, . . . , L}. In the REVAMP study, J = 1 (SERT), K = 1 (SERT), and L = 3 (CBASP,
BSP, and MED). A treatment regime AjBkB
′
l is then defined as “treat with Aj followed
by Bk if respond, by B
′
l if otherwise.” In longitudinal studies, patients are followed over
time, and for patient i, let Yim be the continuous outcome measured at time tim, where
m ∈ {1, . . . ,Mi} and Yi = {Yi1, . . . , YiMi}T .
In the presence of randomization and drop-out, it is often useful to apply the idea of
counterfactuals to the data analysis [Holland, 1986]. For patient i, define Ri(Aj) to be the
response status if he/she had received the first line treatment Aj; let Tim1i be the time
when patient i is declared as a responder or a non-responder to the first line treatment Aj,
at which point randomization to the second set of treatment occurs, m1i ∈ {1, . . . ,Mi}.
Whether observed or not, we define the following outcomes: Yi(Aj), a m1i × 1 vector of
repeated measures of outcome at time points in the first stage if patient i receives treatment
Aj; Yi(AjBk), a (Mi −m1i)× 1 vector of repeated measures of outcome at each time point
in the second stage if patient i receives treatment Aj in the first stage and Bk in the second
stage after responding to Aj; Yi(AjB
′
l), a (Mi − m1i) × 1 vector of repeated measures of
outcome at each time point in the second stage if patient i receives treatment Aj in the first
stage and B′l in the second stage after failing to respond to Aj. For simplicity, let us assume
J = K = L = 2. Thus, for one initial treatment, A1, patient i could be associated with the
following random variables:
{[Ri(A1), Tim1i ] ,Yi(A1),Yi(A1B1),Yi(A1B2),Yi(A1B′1),Yi(A1B′2)} . (3.1)
In terms of these counterfactual variables, we define Yi(A1BkB
′
l) to be an Mi× 1 vector
outcome measurements under treatment regime A1BkB
′
l, for k, l ∈ {1, 2}. The m-th element
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of Yi(A1BkB
′
l) can be expressed as:
Yim(A1BkB
′
l) = I(tim ≤ Tim1i)Yim(A1)
+ I(tim > Tim1i)
{
Ri(A1)Yi(m−m1i)(A1Bk) + [1−Ri(A1)]Yi(m−m1i)(A1B′l)
}
. (3.2)
The counterfactual outcome Yi(A2BkB
′
l) can be defined in a similar fashion. Because pa-
tients who receive the initial treatment A2 are independent samples to patients receiving
A1, without loss of generality, we will focus on one treatment A1 in the first stage. Our
interest is to estimate the effect of treatment regime A1BkB
′
l on the counterfactual outcome
Yim(A1BkB
′
l) over time. In other words, we are focusing on the estimation of the coefficient
β1,1kl in the following marginal mean model,
E[Yim(A1BkB
′
l) | xim] = xTimβ1kl, (3.3)
where xTim = [1, tim, w1i, . . . , wpi], {w1i, . . . , wpi} ∈Wi, and βT1kl = [β0,1kl, . . . , βp+1,1kl].
If Yim(A1BkB
′
l) was observed for each patient in the sample, any conventional statistical
method could have provided valid estimation to these coefficients. However, in reality, we
cannot observe the counterfactual outcome Yim(A1BkB
′
l) for all patients. For example, if a
patient received A1, responded to A1, and then received B2, we do not observe the counter-
factual outcome Yim(A1B1B
′
l) for that patient. The complete observed data are characterized
as the set of i.i.d. random list:
{[Ri, Tim1i ] , RiZki, (1−Ri)Z ′li,Wi,Yi} , for k, l ∈ {1, 2},
where Ri = 1, if the patient is a responder, and Ri = 0 otherwise;Wi is a finite set of baseline
covariates; Zki and Z
′
li are the assignment indicators for treatment Bk and B
′
l, respectively,
for k, l ∈ {1, 2}; Z1i = 1(0) if patient i is randomized to B1(B2); Z ′1i = 1(0) if patient i is
randomized to B′1(B
′
2); Z2i and Z
′
2i satisfy Z1i + Z2i = 1 and Z
′
1i + Z
′
2i = 1; Yi is a Mi × 1
vector of repeated observed outcome for patient i.
In order to draw inference on Yi(A1BkB
′
l) from the observed data Yi, one requires the
consistency assumption (CA) to connect observed data and counterfactuals [Rubin, 1974,
Robins et al., 2000]. The CA implies that the observed outcome is equal to the counterfactual
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outcome under treatment assignment consistent with the counterfactual. In other words, the
m-th element of Yi is:
Yim = I(tim ≤ Tim1i)Yim(A1)
+ I(tim > Tim1i)
{
Ri
2∑
k=1
ZkiYi(m−m1i)(A1Bk) + (1−Ri)
2∑
l=1
Z ′liYi(m−m1i)(A1B
′
l)
}
. (3.4)
Another frequently made assumption is the Sequential Randomization Assumption (SRA)
which states that the probabilities of receiving treatment Bk and B
′
l do not depend on coun-
terfactuals given the history of information collected prior to the randomization [Rubin,
1974, Robins, 1986]:
P {Zki = 1 | [Ri = 1, Tim1i ] ,Wi,Yi(A1BkB′l)} = P {Zki = 1 | [Ri = 1, Tim1i ] ,Wi} ;
P {Z ′li = 1 | [Ri = 0, Tim1i ] ,Wi,Yi(A1BkB′l)} = P {Z ′li = 1 | [Ri = 0, Tim1i ] ,Wi} ;
for k, l ∈ {1, 2}. (3.5)
In the REVAMP study, the second stage treatment assignment probabilities were constant.
Therefore, we define P{Zki = 1 | [Ri = 1, Tim1i ],Wi} = ηk and P{Z ′li = 1 | [Ri =
0, Tim1i ],Wi} = ζl to be constant as well.
3.3 INFERENCE
Our goal is to estimate the effects of treatment regimes A1BkB
′
l where k, l ∈ {1, 2} in reducing
the HRSD scores under the generalized estimating equations (GEE) framework [Liang and
Zeger, 1986]. If Yi(A1BkB
′
l) was observed for all patients, a generalized estimating equation
of the form
n∑
i=1
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl} = 0, (3.6)
could have been used to estimate the effect of treatment regime A1BkB
′
l on the HRSD scores
[by the adjusted time coefficient (continuous time) or by the adjusted change (discrete time)],
where XTi = [xi1, . . . ,xiMi ], and xim is defined as in (3.3); Vi,1kl = φA
1/2
i,1klR(α)A
1/2
i,1kl; R(α)
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is anMi×Mi working correlation matrix specified by α; Ai,1kl is anMi×Mi diagonal matrix
with vim(Xi;β1kl) as the m-th element, where vim(Xi,β1kl) is the assumed working variance
function of Yim(A1BkB
′
l) and φ is the dispersion parameter. But in our setting, Yi(A1BkB
′
l)
cannot be observed for all four possible treatment regimes A1B1B
′
1, A1B1B
′
2, A1B2B
′
1, and
A1B2B
′
2. In this case, all patients belong to all four treatment regimes as long as they
are in the first stage. In the second stage, each patient belongs to at most two treatment
regimes but not all. For example, if a patient received A1 in the first stage and received
B1 in the second stage after responding to A1, he/she would be consistent with regimes
A1B1B
′
1 and A1B1B
′
2 only. However, if a patient was randomized to A1 at the first stage
and dropped out before reaching the second stage, then he/she would be consistent with all
four regimes starting with A1. While estimating the effects of treatment regime A1B1B
′
1,
patients who receive B2 or B
′
2 in the second stage would be considered to have missing data
by study design (i.e. by randomization.) In the presence of missing data by randomization,
the inverse-probability-weighting (IPW) methodology can provide valid estimation [Robins
and Rotnitsky, 1992, Rotnitzky, 2009]. To account for missing data due to randomization in
two-stage longitudinal studies, we construct the m-th element of the diagonal weight matrix
as follows:
Qim,1kl = I(tim ≤ Tim1i) + I(tim > Tim1i)×
[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
]
, (3.7)
where ηk = P (Zki = 1 | [Ri = 1, Tim1i ],Wi), and ζl = P (Z ′li = 1 | [Ri = 0, Tim1i ],Wi).
The term I(tim ≤ Tim1i) in (3.7) represents data from patient i before responding/failing
to respond to A1. By including the information of time to response, Tim1i , all patients’
information collected on or before time Tim1i will be used in the analysis, even if he/she was
not consistent with the target treatment regime due to treatment assignment in the second
stage. After the response status of patient i is confirmed, where (tim > Tim1i) in (3.7), his/her
data will be inversely weighted by ηk or ζl based on the response status, Ri, and treatment
allocation, Zki or Z
′
li, [η
−1
k RiZki + ζ
−1
l (1− Ri)Z ′li] in (3.7). Therefore, Qim,1kl ≥ 1 if patient
i is consistent with regime A1BkB
′
l, otherwise Qim,1kl = 0. The weight matrix Qi,1kl is thus
an Mi ×Mi matrix, diag(Qim,1kl,m = 1, . . . ,Mi).
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Lemma 3.3.1. Under SRA in (3.5), E[Qi,1kl | Xi,Yi(A1BkB′l)] = IMi.
Proof. Using iterated conditioning,
E [Qim,1kl | Xi,Yi(A1BkB′l)]
= E
{
I(tim ≤ Tim1i) + I(tim > Tim1i)
[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
]
| Xi,Yi(A1BkB′l)
}
= E
(
E
{
I(tim ≤ Tim1i) + I(tim > Tim1i)
[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
]
| [Ri, Tim1i ] ,Xi,Yi(A1BkB′l)
})
= E
{
I(tim ≤ Tim1i) + I(tim > Tim1i)× E
[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
| [Ri, Tim1i ] ,Xi,Yi(A1BkB′l)
]}
= E [I(tim ≤ Tim1i) + I(tim > Tim1i)] (by SRA in (3.5))
= 1.
In longitudinal studies, drop-out is a common phenomenon. To account for the partial
information observed from patients who dropped out from the study, we re-define the m-th
element of the diagonal weight matrix from (3.7) as
Qim,1kl(piim) =
∆im
piim
×
{
I(tim ≤ Tim1i) + I(tim > Tim1i)×
[
RiZki
ηk
+
(1−Ri)Z ′li
ζl
]}
,
where ∆im is the indicator for observing outcome data from patient i at time tim, i.e. ∆im = 1
if observed and ∆im = 0 if otherwise. Let piim denote the probability of observing the
outcome for patient i at time tim given that the patient had data up to time ti(m−1), where
piim = P (∆im = 1 | ∆i(m−1) = 1), m > 1. Thus, piim is the unconditional probability of
observing the outcome at the m-th time point for the i-th patient, where piim =
∏m
s=2 piis.
Note that we assume monotone missing, i.e. ∆im = 0 implies ∆i(m+1) = . . . = ∆iMi = 0.
We also assume that all outcome data are observed at baseline, i.e. ∆i1 = 1 and pii1 = 1 for
all patients. Therefore, each patient who was consistent with the treatment regime and had
observed data at time tim is additionally and inversely weighted by piim.
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Lemma 3.3.2. Under SRA in (3.5), and when piim is known, E[Qi,1kl(piim) | Xi,Yi(A1BkB′l)] =
IMi.
Proof. Using iterated conditioning,
E [Qim,1kl(piim) | Xi,Yi(A1BkB′l)]
= E
{
E
[
∆im
piim
Qim,1kl | ∆im, [Ri, Tim1i ] ,Xi,Yi(A1BkB′l)
]}
= E
{
∆im
piim
E [Qim,1kl | ∆im, [Ri, Tim1i ] ,Xi,Yi(A1BkB′l)]
}
= E
[
∆im
piim
]
(by Lemma 3.3.1)
= E
{
1
piim
E [∆im|Xi,Yi(A1BkB′l)]
}
=
1
piim
×
m∏
s=2
piis
= 1, for m = 2, . . . ,Mi.
In most of the cases, piim is unknown and needs to be estimated. Let piim(γ) = Gim(γ)
be a postulated model for drop-out process defined by a set of parameters γ. Let γˆ be a
regular and asymptotically linear (RAL) estimator of γ. For each patient i who is consistent
with treatment regime A1BkB
′
l, we define the weight matrix, Qi,1kl(γˆ), as the Mi × Mi
diagonal matrix, where each m-th diagonal element is Qim,1kl(γˆ) = pi
−1
im(γˆ)∆imQim,1kl, where
piim(γˆ) =
∏m
s=2Gim(γˆ). This modified weight is then used in the estimating equation (3.6).
Specifically, the weighted estimating equations can be expressed as
n∑
i=1
Ui (β1kl, γˆ) =
n∑
i=1
XTi V
−1
i,1klQi,1kl(γˆ) {Yi −Xiβ1kl} = 0. (3.8)
The solution of (3.8) can be obtained through the following iterative algorithm [Liang and
Zeger, 1986]:
βˆ
(r+1)
1kl = βˆ
(r)
1kl +
[
n∑
i=1
XTi V
−1
i,1klQi,1kl(γˆ)Xi
]
−1 n∑
i=1
XTi V
−1
i,1klQi,1kl(γˆ)
[
Yi −Xiβˆ(r)1kl
]
. (3.9)
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Lemma 3.3.3. Under CA in (3.4), SRA in (3.5), and when piim = Gim(γ) is correctly
specified, E [Ui(β1kl,γ)] = 0.
Proof. Under CA in (3.4), Qi,1kl(γ)Yi = Qi,1kl(γ)Yi(A1BkB
′
l). Thus,
E [Ui (β1kl,γ)] = E
[
XTi V
−1
i,1klQi,1kl(γ) {Yi −Xiβ1kl}
]
= E
[
XTi V
−1
i,1klQi,1kl(γ) {Yi(A1BkB′l)−Xiβ1kl}
]
(by CA in (3.4))
= E
{
E
[
XTi V
−1
i,1klQi,1kl(γ) {Yi(A1BkB′l)−Xiβ1kl}
∣∣Xi,Yi(A1BkB′l)]}
= E
[
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl}
]
(by Lemma 3.3.2)
= E
{
E
[
XTi V
−1
i,1kl {Yi(A1BkB′l)−Xiβ1kl} |Xi
]}
= E
{
XTi V
−1
i,1kl {E [Yi(A1BkB′l)|Xi]−Xiβ1kl}
}
= 0 (by Equation (3.3)).
Proposition 3.3.1. βˆ1kl is a consistent estimator of β1kl, provided (1) γˆ is
√
n-consistent,
(2) piim = Gim(γ) is specified correctly, and (3) piim does not depend on the counterfactuals.
Proof. From (1), we can write
√
n (γˆ − γ) = n− 12 ∑ni=1ϕi(γ) + op(1), where ϕi(γ) is the
influence function of the estimator γˆ and E[ϕi(γ)] = 0. Since βˆ1kl satisfies Equation (3.8),
the estimator (βˆ1kl, γˆ)
T is an M-estimator [Stefanski and Boos, 2002] defined by
n∑
i=1
Ψi(β1kl,γ) =
n∑
i=1
 Ui (β1kl,γ)ϕi(γ)
 = 0.
The consistency of βˆ1kl follows from the fact that E[Ψi(β1kl,γ)] = 0 (by Lemma 3.3.3).
Proposition 3.3.2. Under assumptions similar to Proposition 3.3.1, βˆ1kl is an asymptoti-
cally normally distributed with mean β1kl and variance Σ/n, where
Σ =
[
E
(
XTi V
−1
i,1klXi
)]
−1
B (φ,α,β1kl,γ)
[
E
(
XTi V
−1
i,1klXi
)]
−1
, and (3.10)
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B (φ,α,β1kl,γ) =E
[
Ui (β1kl,γ)Ui (β1kl,γ)
T
]
+ E
[
Ui (β1kl,γ)ϕi(γ)
T
]× E [ ∂
∂γT
Ui (β1kl,γ)
]T
+ E
[
∂
∂γT
Ui (β1kl,γ)
]
× E
[
ϕi(γ)Ui (β1kl,γ)
T
]
+ E
[
∂
∂γT
Ui (β1kl,γ)
]
× E [ϕi(γ)ϕi(γ)T ]× E [ ∂∂γTUi (β1kl,γ)
]T
.
Proof. We start with the fact that the estimator βˆ1kl satisfies
∑n
i=1Ui(βˆ1kl, γˆ) = 0. First,
expanding
∑n
i=1Ui(βˆ1kl, γˆ) around β1kl using Taylor’s expansion, we obtain
n
1
2
(
βˆ1kl − β1kl
)
=
[
− 1
n
n∑
i=1
∂
∂βT1kl
Ui (β1kl, γˆ)
]
−1
n−
1
2
n∑
i=1
Ui (β1kl, γˆ) + op(1) (3.11)
Then, applying Taylor’s expansion on (3.11) around γ, (3.11) can be rewritten as
n
1
2 (βˆ1kl − β1kl) =
[
− 1
n
n∑
i=1
∂
∂βT1kl
Ui (β1kl,γ)
]
−1
n−
1
2
n∑
i=1
Ui (β1kl,γ)
+

[
− 1
n
n∑
i=1
∂2
∂βT1kl∂γ
T
Ui (β1kl,γ)
]
−1
1
n
n∑
i=1
Ui (β1kl,γ)
+
[
− 1
n
n∑
i=1
∂
∂βT1kl
Ui (β1kl,γ)
]
−1
1
n
n∑
i=1
∂
∂γT
Ui (β1kl,γ)
× n 12 (γˆ − γ) + op(1). (3.12)
As n→∞,
− 1
n
n∑
i=1
∂
∂βT1kl
Ui (β1kl,γ)→ E
(
XTi V
−1
i,1klXi
)
(3.13)
1
n
n∑
i=1
Ui (β1kl, γ)→ 0 (by Lemma 3.3.3), and (3.14)
1
n
n∑
i=1
∂
∂γT
Ui (β1kl,γ)→ E
[
∂
∂γT
Ui (β1kl,γ)
]
. (3.15)
Since γˆ is
√
n-consistent, we can write
√
n(γˆ −γ) = n−1/2∑ni=1ϕi(γ)+ op(1), where ϕi(γ)
is the influence function of the estimator γˆ and E[ϕi(γ)] = 0. Using (3.13)–(3.15), we can
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rewrite (3.12) as n1/2(βˆ1kl − β1kl) = n−1/2
∑n
i=1ψi,1kl + op(1) where ψi,1kl is the influential
function of βˆ1kl and it can be expressed as
ψi,1kl =
[
E
(
XTi V
−1
i,1klXi
)]
−1
{
Ui (β1kl,γ) + E
[
∂
∂γT
Ui (β1kl,γ)
]
ϕi(γ)
}
. (3.16)
By the central limit theorem, we can deduce that n1/2(βˆ1kl − β1kl) d−→ MVN(0,Σ) where
Σ = E(ψi,1klψ
T
i,1kl) and is given in (3.10).
Let γ be a (q + 1) × 1 vector, i.e. γ = [γ0, . . . , γq]T ; therefore, E[ ∂∂γTUi (β1kl,γ)] will
be a (q + 1)× (p+ 2) matrix. Each column of matrix E[ ∂
∂γT
Ui (β1kl,γ)] is the result of the
partial derivative with respect to γ0, . . . , γq, respectively. Therefore,
E
[
∂
∂γT
Ui (β1kl,γ)
]
= E
[
∂
∂γ0
Ui (β1kl,γ) ; . . . ;
∂
∂γq
Ui (β1kl,γ)
]
= E
[
∂
∂γ0
XTi V
−1
i,1klQi,1kl(γ) (Yi −Xiβ1kl) ; . . . ;
∂
∂γq
XTi V
−1
i,1klQi,1kl(γ) (Yi −Xiβ1kl)
]
= E
{
XTi V
−1
i,1kl
[
∂
∂γ0
Qi,1kl(γ)
]
(Yi −Xiβ1kl) ; . . . ;XTi V−1i,1kl
[
∂
∂γq
Qi,1kl(γ)
]
(Yi −Xiβ1kl)
}
= E
{
XTi V
−1
i,1klΓi0(γ)Qi,1kl(γ) (Yi −Xiβ1kl) ; . . . ;XTi V−1i,1klΓiq(γ)Qi,1kl(γ) (Yi −Xiβ1kl)
}
,
where
Γis(γ) = diag
{[
−
1∑
v=1
G−1iv (γ)
∂
∂γs
Giv(γ)
]
, . . . ,
[
−
Mi∑
v=1
G−1iv (γ)
∂
∂γs
Giv(γ)
]}
,
for s = 0, . . . , q.
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3.4 SIMULATION STUDY
To evaluate the performance of our proposed IPWGEE estimators in small samples, we
conducted several simulation studies. We simulated data from a population which has similar
design to the REVAMP study. Each patient had repeated measurements at seven visits
such that tTi = [ti1, . . . , ti7] = [0, 2, 4, 6, 8, 10, 12] for patient i. We considered one initial
treatment A1, two second stage treatments, B1 and B2, for responders, and two second stage
treatments, B′1 and B
′
2, for non-responders. All patients received initial treatment A1 at
ti1 = 0. For each patient i, we generated counterfactual random variables listed in (3.1).
Similar to the REVAMP study, patients were assessed to see if they had responded to the
initial treatment A1 at ti3 = 4 and ti4 = 6. Thus, the index of the time of response in this
case is m1i = 3 or 4. The response status, Ri, was drawn from a Bernoulli(θ) distribution.
We assume that of these responders, 100×θ1% responded at time ti3 and the rest at time ti4.
Thus each responder was assigned randomly to respond at time ti3 with probability θ1. We
considered two sets of parameters, (θ, θ1) = (0.5, 0.25) and (0.3, 0.15) meaning 50% (30%)
of the subjects would respond of whom 25% (15%) would respond at time ti3 and the rest
at time ti4. We also generated a baseline covariate, age, which follows a normal distribution
with mean µage = 45 and standard deviation σage = 11. For each patient i, counterfactual
outcome vectors Yi(A1), Yi(A1B1), Yi(A1B2), Yi(A2B1), and Yi(A2B
′
2), were generated
from the following multivariate normal distributions (MVN):
Yi(A1) ∼ MVNm1i((θ1,A1 + θ2,A1 × agei)× 1m1i + θ3,A1 × t0i,Σ0),
Yi(A1B1) ∼ MVN7−m1i((θ1,A1B1 + θ2,A1B1 × agei)× 1(7−m1i) + θ3,A1B1 × t1i,Σ1),
Yi(A1B2) ∼ MVN7−m1i((θ1,A1B2 + θ2,A1B2 × agei)× 1(7−m1i) + θ3,A1B2 × t1i,Σ1),
Yi(A1B
′
1) ∼ MVN7−m1i((θ1,A1B′1 + θ2,A1B′1 × agei)× 1(7−m1i) + θ3,A1B′1 × t1i,Σ1),
and Yi(A1B
′
2) ∼ MVN7−m1i((θ1,A1B′2 + θ2,A1B′2 × agei)× 1(7−m1i) + θ3,A1B′2 × t1i,Σ1),
where t0i is an m1i × 1 vector which indicates visits of outcome measurements in the first
stage and t1i is a (7 − m1i) × 1 vector which indicates visits of outcome measurements in
the second stage; Σ0(σ0, ρ0) is an m1i×m1i covariance matrix defined by standard deviation
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σ0 and autoregressive correlation ρ0; Σ1(σ1, ρ1) is a (7−m1i)× (7−m1i) covariance matrix
defined by standard deviation σ1 and autoregressive correlation ρ1. The values of σ0, σ1, ρ0,
and ρ1 were set to be 5, 3, 0.8, and 0.8, respectively. For each patient i, the m-th element of
the counterfactual outcome under a treatment regime A1BkB
′
l for k, l ∈ {1, 2} is generated
by (3.2). The main focus in this study was to estimate the parameters β1kl in the model
E[Yim(A1BkB
′
l) | xim] = xTimβ1kl, where xim = [1, tim, agei]T .
We considered the following parameter values for each counterfactual vector: θ1,A1= 25,
θ2,A1= 0.5, θ3,A1= -0.5, θ1,A1B1= 27, θ2,A1B1= 0.6, θ3,A1B1= -1.5, θ1,A1B2= 38, θ2,A1B2= 0.4,
θ3,A1B2= -2, θ1,A1B′1= 36, θ2,A1B′1= 0.7, θ3,A1B′1= -3, θ1,A1B′2= 68, θ2,A1B′2= 0.3, and θ3,A1B′2=
-5. For this population, the true parameter values were βT111 = [23.09,−1.13, 0.57], βT112 =
[27.94,−1.53, 0.48], βT121 = [25.45,−1.30, 0.52], and βT122 = [30.38,−1.69, 0.43] for 50% re-
sponse, and βT111 = [22.88,−1.20, 0.58], βT112 = [29.65,−1.77, 0.45], βT121 = [24.28,−1.31, 0.55],
and βT122 = [31.10,−1.86, 0.42] for 30% response.
2000 Monte Carlo samples of sizes 250, 500, and 900 observations were drawn from the
populations described above with the following characteristics. For responders (i.e. Ri = 1),
the assignment indicator for treatment B1, Z1i, was drawn from a Bernoulli distribution with
probability η1; the assignment indicator for treatment B2 was defined as Z2i = 1− Z1i. For
non-responders (i.e. Ri = 0), the assignment indicator for treatment B
′
1, Z
′
1i was drawn from
a Bernoulli distribution with probability ζ1; the assignment indicator for treatment B
′
2 was
defined as Z ′2i = 1−Z ′1i. We assumed parameters {η1, ζ1} to be {0.5, 0.5}. Then, we defined
the observed outcome for patient i at time tim as in (3.4).
Additionally, a number of patients were allowed to drop out at each time point based
on the following logistic regression model: piim = Gim(γ) = {1 + exp[−γ0 − γ1 × tim −
γ2 × agei − γ3 × Yi(m−1) − γ4 × tim × agei − γ5 × tim × Yi(m−1)]}−1. Choices of parameters
γT = [2.1, 0.11, 0.01,−0.02, 0.001,−0.002] and γT = [2.42, 0.1, 0.02,−0.04, 0.002,−0.006]
gave us approximate drop-out rates of 30% and 50%, respectively.
Table 3.1 shows the simulation results of the IPWGEE estimators under the scenarios
of 50% response rate. When the drop-out rate was 30%, the IPWGEE estimators were
approximately unbiased for all regimes with a sample size of 250. The maximum relative
bias observed was 0.8%. The estimated standard errors of the estimators were consistent with
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the Monte Carlo standard errors. The coverage probabilities for the 95% Wald confidence
intervals for the parameters were ranged between 94.1% and 94.9%. When the sample size
was increased, the results remained the same for all regimes as expected. When the drop-
out rate was 50% and the sample size was 250, the maximum relative bias of the estimators
increased to 1.8%. The estimated standard errors of the estimators were slightly inconsistent
with the Monte Carlo standard deivations. When the sample size was increased to 500 and
900, the estimators were approximately unbiased for all regimes with the maximum relative
bias of 1.3%. The estimated standard errors of the estimators were consistent with the Monte
Carlo standard errors. For the sample size of 900, the coverage probabilities for the 95%
Wald confidence intervals for the parameters were ranged between 91.9% and 94.3%.
For the scenarios of 30% response rate (shown in Table 3.2), the IPWGEE estimators
were approximately unbiased for all regimes regardless the size of the sample. The maximum
relative biases observed were 1.5% for 30% drop-out rate and 1.7% for 50% drop-out rate.
Similar to the resutls presented in Table 3.1, the estimated standard errors of the estimators
were consistent with the Monte Carlo standard errors when the drop-out rate was 30%.
For the drop-out rate of 50%, a large size of sample was needed in order to observe the
consistency between the estimated standard errors of the estimators and the Monte Carlo
standard errors. For the sample size of 900, the coverage probabilities for the 95% Wald
confidence intervals for the parameters were ranged between 91.9% and 93.3% for 30% drop-
out and ranged between 91.7% and 94.3% for 50% drop-out.
In both Tables 3.1 and 3.2, the IPWGEE estimators gained efficiency with increasing
sample size. The estimated standard errors of the estimators and the Monte Carlo standard
errors were closer to each other when the sample size became larger. When the drop-out
rate increased, the IPWGEE estimators required a larger sample size in order to achieve the
consistency.
Table 3.3 shows the comparisons of the IPWGEE estimators based on subject-specific and
time-dependent weights under the scenarios of 50% response rate. Regardless the drop-out
rates, both weighting methods provided unbiased estimators among four treatment regimes.
Because of the additional information incorporated in the time-dependent weighting method,
its Monte Carlo standard errors were relatively smaller than the Monte Carlo standard errors
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provided by subject-specific weighting method. For example, for regime A1B1B
′
1 with a
sample size of 250 and 30% drop-out rate, the Monte Carlo standard error was 0.070 for
subject-specific weighting method and 0.052 for time-dependent weighting method. Similar
results were found under the scenarios of 30% response rate (Table 3.4).
3.5 ANALYSIS OF THE REVAMP STUDY
A total of 618 patients with chronic forms of major depressive disorders received Sertraline
(SERT) as the initial treatment in the REVAMP study for a maximum of 12 weeks [Trivedi
et al., 2008]. During weeks 8 through 12 in the first stage, the response status to SERT
from each patient was determined. Patients responding to SERT continued receiving SERT
in the second stage for another 12 weeks. Patients failing to respond to SERT were ran-
domized to additionally receive one the the following three treatments for another 12 weeks:
(1) Cognitive Behavior Analysis System of Psychotherapy (CBASP), (2) Brief Supportive
Psychotherapy (BSP), or (3) Medication alone (MED). The randomization was done with
probabilities of 0.4, 0.4, and 0.2, respectively, to CBASP, BSP, and MED. The outcome of
the study was measured by the 24-item Hamilton Rating Scale for Depression (HRSD) scores
at each visit. A reduction of the HRSD scores from baseline would indicate that the patient
was recovering from depression.
Figure 3.1 depicts the design and patient flow of 618 patients in the REVAMP study.
In the first stage, 125 patients responded to SERT and 357 patients failed to respond to
SERT. In the first stage, 136 patients dropped out from the study at different points of time
prior to ascertaining their response status. In the second stage, 125 responders continued
receiving SERT and 101 of them had; thus 24 patients’ HRSD scores were missing at one or
more time points. Among 357 patients who did not respond to SERT, 137 received CBASP
(120 of them had complete HRSD scores), 147 received BSP (123 of them had complete
HRSD scores), and 73 received MED (56 of them had complete HRSD scores). Overall, 218
patients (136 in the first stage and 82 in the second stage) did not have complete HRSD
scores but had partial observations prior to drop-out. Figure 3.2 illustrates how the HRSD
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scores changed over time in different groups. For responders (Figure 3.2(a)), their HRSD
scores dropped rapidly from the beginning to the end of study. For non-responders, the
reductions of the HRSD scores from baseline were similar to each other among CBASP,
BSP, and MED (Figures 3.2(b), 3.2(c), and 3.2(d), respectively), and their slopes were much
smaller compared to responders’ slope. For drop-outs (Figure 3.2(e)), the reduction of the
HRSD scores from baseline showed a flat trend and the variation was the largest among five
groups.
Our goal was to estimate the effects of all possible depression treatment regimes in
reducing the HRSD scores in the REVAMP study. Hence, starting with initial treatment
SERT, there are three depression treatment regimes for which the REVAMP study: (1) SSC:
treat with SERT, continue SERT if respond, otherwise add CBASP to SERT; (2) SSB: treat
with SERT, continue SERT if respond, otherwise add BSP to SERT; and (3) SSM: treat
with SERT, continue SERT if respond, otherwise add MED to SERT. Therefore, responders
with SERT in Figure 3.2(a) and non-responders with CBASP in Figure 3.2(b) are consistent
with depression treatment regime SSC. Responders with SERT in Figure 3.2(a) and non-
responders with BSP in Figure 3.2(c) are consistent with depression treatment regime SSB.
Responders with SERT in Figure 3.2(a) and non-responders with MED in Figure 3.2(d) are
consistent with depression treatment regime SSM. The effects of depression treatment regime
r, where r ∈ {SSC, SSB, SSM}, could be formulated as the coefficient βr in the marginal
mean model E[HRSDim(r) | tim, w1i, . . . , wpi] = β0,r+β1,r×tim+β2,r×w1i+ . . .+βp+1,r×wpi,
where {w1i, . . . , wpi} ∈Wi. The selection of baseline covariates in the marginal mean model
were determined by the analysts through knowledge about the study or the standard model-
building process. We chose age and employment status as the baseline covariates along with
an interaction between time and age in the marginal mean model. Hence, the marginal mean
model for depression treatment regime r is
E [HRSDim(r) | tim, agei, empi]
= β0,r + β1,r × tim + β2,r × agei + β3,r × empi + β4,r × tim × agei,
where empi=1 if employed and empi=0 if otherwise. The inference was drawn from the
observed outcome Yim using the IPWGEE methodology.
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Figure 2(e) shows data from 218 patients who had dropped out from the REVAMP study.
Their HRSD scores were not available starting after drop-out. However, these patients’
HRSD scores collected prior to drop-out could provide useful partial information. Table 3.5
shows the distributions of drop-outs across baseline covariates. In univariate analysis using
chi-square test (or Fisher’s exact test) with level of 0.05, Caucasian race, higher education,
and older age were significantly associated with having complete data. To account for the
incompleteness through the IPWGEE methodology, the conditional probability of observing
the HRSD scores for patient i at time tim, piim, was estimated from the sample based on
a logistic regression model. Based on the results in Table 3.5, we postulated a multiple
logistic regression model with backward selection process to estimate piim. The logistic
regression model can be written as follows: pˆiim = Gim(γˆ) = [1 + exp(O
T
imγˆ)]
−1, where
OTim = {I(tim = ti2), . . . , I(tim = ti13), edui,HRSDi(m−1), agei,HRSDi(m−1) × agei}.
Table 3.6 shows the results of analyzing data from the REVAMP study. We performed
the complete-case (CC) and the available-case (AC) with IPWGEE analyses. The standard
error of the estimates from the AC with IPWGEE were slightly smaller than those from
the CC. Controlling for the employment status, for a patient of age 43 years, the treatment
regime SSB will have the highest reduction of 0.759 per week in the HRSD scores from
baseline, followed by the treatment regime SSC (0.693/week) and then by the treatment
regime SSM (0.559/week) in the CC analysis. On the contrary, the treatment regime SSB
had the highest reduction of 0.780 per week in the HRSD scores from baseline, followed by
the treatment regime SSM (0.729/week) and then by the treatment regime SSC (0.710/week)
in the AC with IPWGEE analysis. In both analyses, the effect of each treatment regime
was statistically significant (p<0.001). To compare the effects across treatment regimes
SSC, SSB, and SSM, we used the Wald test discussed in Section 2.5. In Table 3.7, Wald
Chi-square tests comparing the effects of treatment regimes (H0 : β1,SSC + β4,SSC × 43 =
β1,SSB+β4,SSB×43 = β1,SSM +β4,SSM ×43) with 2 degrees of freedom resulted in a p-values
of 0.500 in the CC analysis and 0.363 in the AC with IPWGEE analysis. Both methods
indicated that there was no evidence that the effects of these three treatment regimes were
significantly different from each other.
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3.6 DISCUSSION
Missing data is a common phenomenon in longitudinal studies. Missing data can be broadly
attributed to two sources: (1) study design or randomization, and (2) drop-out from the
study. In a two-stage longitudinal study, such as the one presented here, in the second stage of
the study, patients randomized to one treatment can not receive other competing treatments.
Additionally, if the drop-out occurs prior to the second stage, a patient’s response status may
not be observed. To account for these two sources of missing data, we have used the inverse-
probability-weighted generalized estimating equations (IPWGEE) method (Robins et al.,
1995) to take into account the missing data due to randomization and drop-out. The weights
are formed by inversely weighting the probability of randomization to the treatment dictated
by the regime and the probability of observing outcome data at each visit. In this Chapter, we
have constructed time-dependent weights to take into account the partial information from
patients who received other competing treatments and patients who dropped out from the
study. The probability of observing outcome data at each visit is estimated through a logistic
regression model. We show that the IPWGEE estimators are consistent and asymptotically
normal. We have demonstrated our methods using a dataset from a depression study.
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3.7 FIGURES AND TABLES
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Figure 3.1: Patient flow in the REVAMP study.
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(a) Responders with SERT
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(b) Non-responders with CBASP
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(c) Non-responders with BSP
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(d) Non-responders with MED
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(e) Drop-outs
Figure 3.2: HRSD scores of patients in the REVAMP study. Thick lines indicate
the mean of HRSD scores at each visit. (CBASP: Cognitive Behavior Analysis System of
Pychotherapy; BSP: Brief Supportive Psychotherapy; MED: Medication alone)
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Table 3.1: Simulation results of βˆ1,1kl based on 2000 Monte Carlo samples of sizes
250, 500, and 900 with 50% response rate. EST is MC mean of estimates, SE is MC
mean of estimated standard errors, MCSE is standard error of MC estimates, and CP is
empirical coverage probability.
Sample Regime True EST (SE) MCSE CP% EST (SE) MCSE CP%
Size Value
30% drop-out rate 50% drop-out rate
250 A1B1B
′
1 -1.13 -1.13 (0.050) 0.052 94.0 -1.12 (0.074) 0.083 91.3
A1B1B
′
2 -1.53 -1.52 (0.085) 0.086 94.9 -1.51 (0.133) 0.145 91.0
A1B2B
′
1 -1.30 -1.29 (0.048) 0.049 94.7 -1.29 (0.070) 0.078 91.8
A1B2B
′
2 -1.69 -1.68 (0.070) 0.070 94.1 -1.68 (0.109) 0.117 92.2
500 A1B1B
′
1 -1.13 -1.13 (0.036) 0.036 94.5 -1.13 (0.054) 0.058 92.4
A1B1B
′
2 -1.53 -1.52 (0.061) 0.065 93.2 -1.51 (0.097) 0.104 91.3
A1B2B
′
1 -1.30 -1.29 (0.034) 0.035 93.5 -1.29 (0.050) 0.055 92.4
A1B2B
′
2 -1.69 -1.69 (0.050) 0.053 94.3 -1.68 (0.079) 0.085 91.3
900 A1B1B
′
1 -1.13 -1.13 (0.027) 0.027 94.3 -1.13 (0.040) 0.041 94.3
A1B1B
′
2 -1.53 -1.52 (0.045) 0.047 93.5 -1.51 (0.074) 0.077 92.1
A1B2B
′
1 -1.30 -1.29 (0.026) 0.027 93.5 -1.29 (0.038) 0.039 94.0
A1B2B
′
2 -1.69 -1.69 (0.037) 0.038 93.5 -1.68 (0.059) 0.062 91.9
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Table 3.2: Simulation results of βˆ1,1kl based on 2000 Monte Carlo samples of sizes
250, 500, and 900 with 30% response rate. EST is MC mean of estimates, SE is MC
mean of estimated standard errors, MCSE is standard error of MC estimates, and CP is
empirical coverage probability.
Sample Regime True EST (SE) MCSE CP% EST (SE) MCSE CP%
Size Value
30% drop-out rate 50% drop-out rate
250 A1B1B
′
1 -1.21 -1.20 (0.051) 0.052 93.8 -1.20 (0.075) 0.076 95.3
A1B1B
′
2 -1.76 -1.74 (0.082) 0.084 93.7 -1.72 (0.132) 0.145 91.7
A1B2B
′
1 -1.31 -1.29 (0.049) 0.050 93.1 -1.30 (0.071) 0.075 94.5
A1B2B
′
2 -1.86 -1.84 (0.069) 0.072 92.5 -1.83 (0.109) 0.120 89.5
500 A1B1B
′
1 -1.21 -1.20 (0.036) 0.037 93.0 -1.19 (0.054) 0.060 91.2
A1B1B
′
2 -1.76 -1.74 (0.059) 0.055 94.6 -1.73 (0.095) 0.097 93.1
A1B2B
′
1 -1.31 -1.29 (0.035) 0.037 91.1 -1.29 (0.051) 0.055 92.1
A1B2B
′
2 -1.86 -1.84 (0.049) 0.046 91.7 -1.84 (0.078) 0.081 92.5
900 A1B1B
′
1 -1.21 -1.20 (0.027) 0.028 92.9 -1.19 (0.041) 0.041 94.3
A1B1B
′
2 -1.76 -1.74 (0.044) 0.043 93.3 -1.73 (0.072) 0.076 91.7
A1B2B
′
1 -1.31 -1.29 (0.026) 0.027 91.9 -1.29 (0.039) 0.040 92.0
A1B2B
′
2 -1.86 -1.84 (0.037) 0.036 91.7 -1.83 (0.059) 0.062 91.9
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Table 3.3: Comparisons of subject-specific and time-dependent weights for estimating β1,1kl based on 2000 Monte
Carlo samples of 50% response rate. EST is MC mean of estimates and MCSE is standard error of MC estimates.
Subject-Specific Weight Time-Dependent Weight
30% Drop-out 50% Drop-out 30% Drop-out 50% Drop-out
Size Regime Truth EST MCSE EST MCSE EST MCSE EST MCSE
250 A1B1B
′
1 -1.13 -1.13 0.070 -1.13 0.136 -1.13 0.052 -1.12 0.083
A1B1B
′
2 -1.53 -1.53 0.099 -1.53 0.182 -1.52 0.086 -1.51 0.145
A1B2B
′
1 -1.30 -1.30 0.064 -1.29 0.128 -1.29 0.049 -1.29 0.078
A1B2B
′
2 -1.69 -1.70 0.083 -1.69 0.152 -1.68 0.070 -1.68 0.117
500 A1B1B
′
1 -1.13 -1.13 0.050 -1.13 0.100 -1.13 0.036 -1.13 0.058
A1B1B
′
2 -1.53 -1.53 0.072 -1.53 0.131 -1.52 0.065 -1.51 0.104
A1B2B
′
1 -1.30 -1.30 0.047 -1.30 0.093 -1.29 0.035 -1.29 0.055
A1B2B
′
2 -1.69 -1.70 0.059 -1.69 0.111 -1.69 0.053 -1.68 0.085
900 A1B1B
′
1 -1.13 -1.13 0.037 -1.14 0.067 -1.13 0.027 -1.13 0.041
A1B1B
′
2 -1.53 -1.53 0.053 -1.53 0.100 -1.52 0.047 -1.51 0.077
A1B2B
′
1 -1.30 -1.30 0.034 -1.30 0.059 -1.29 0.027 -1.29 0.039
A1B2B
′
2 -1.69 -1.70 0.044 -1.70 0.078 -1.69 0.038 -1.68 0.062
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Table 3.4: Comparisons of subject-specific and time-dependent weights for estimating β1,1kl based on 2000 Monte
Carlo samples of 30% response rate. EST is MC mean of estimates and MCSE is standard error of MC estimates.
Subject-Specific Weight Time-Dependent Weight
30% Drop-out 50% Drop-out 30% Drop-out 50% Drop-out
Size Regime Truth EST MCSE EST MCSE EST MCSE EST MCSE
250 A1B1B
′
1 -1.21 -1.20 0.071 -1.21 0.132 -1.20 0.052 -1.20 0.076
A1B1B
′
2 -1.76 -1.76 0.094 -1.76 0.174 -1.74 0.084 -1.72 0.145
A1B2B
′
1 -1.31 -1.30 0.067 -1.31 0.135 -1.29 0.050 -1.30 0.075
A1B2B
′
2 -1.86 -1.86 0.082 -1.86 0.152 -1.84 0.072 -1.83 0.120
500 A1B1B
′
1 -1.21 -1.21 0.045 -1.20 0.099 -1.20 0.037 -1.19 0.060
A1B1B
′
2 -1.76 -1.76 0.058 -1.76 0.124 -1.74 0.055 -1.73 0.097
A1B2B
′
1 -1.31 -1.30 0.046 -1.30 0.091 -1.29 0.037 -1.29 0.055
A1B2B
′
2 -1.86 -1.86 0.052 -1.86 0.104 -1.84 0.046 -1.84 0.081
900 A1B1B
′
1 -1.21 -1.20 0.037 -1.20 0.069 -1.20 0.028 -1.19 0.041
A1B1B
′
2 -1.76 -1.76 0.050 -1.76 0.097 -1.74 0.043 -1.73 0.076
A1B2B
′
1 -1.31 -1.30 0.035 -1.30 0.064 -1.29 0.027 -1.29 0.040
A1B2B
′
2 -1.86 -1.86 0.042 -1.86 0.080 -1.84 0.036 -1.83 0.062
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Table 3.5: Drop-out rates by baseline characteristics.
Characteristics Complete (n=400) Drop-out (n=218) p-value
n (%) n (%)
Age (years)
Age ≤ 46 185 (53.9) 158 (46.1) <0.01
Age > 46 214 (78.1) 60 (21.9)
Missing, No. 1 0
Sex
Male 185 (66.1) 95 (33.9) 0.52
Female 215 (63.6) 123 (36.4)
Caucasian Race
Yes 344 (66.9) 170 (33.1) 0.01
No 56 (53.9) 48 (46.2)
Hispanic ethnicity
Yes 33 (58.9) 23 (41.1) 0.34
No 362 (65.3) 192 (34.7)
Missing, No. 5 3
Employment
Employed 255 (66.9) 126 (33.1) 0.12
Unemployed 141 (60.8) 91 (39.2)
Missing, No. 4 1
Education
≤ High school 139 (53.9) 119 (46.1) <0.01
> High school 241 (71.5) 96 (28.5)
Missing, No. 20 3
Marital status
Married 158 (68.7) 72 (31.3) 0.10
Not married 238 (62.1) 145 (37.9)
Missing, No. 4 1
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Table 3.6: Results of estimating the effects of treatment regimes in the REVAMP
study using complete-case and IPWGEE analyses.
Complete-Case IPWGEE
Treatment Effect Estimated Standard p-value Estimated Standard p-value
Regime Parameter Error Parameter Error
SSC 1 Intercept 27.192 1.676 <0.001 26.042 1.332 <0.001
Time -0.865 0.094 <0.001 -0.882 0.093 <0.001
Age 0.015 0.030 0.627 -0.011 0.025 0.647
Employment -1.783 0.895 0.046 -2.030 0.845 0.016
Time×Age 0.004 0.002 0.069 0.004 0.002 0.026
SSB 2 Intercept 27.185 1.517 <0.001 26.369 1.127 <0.001
Time -0.931 0.079 <0.001 -0.955 0.072 <0.001
Age -0.010 0.028 0.705 0.004 0.021 0.853
Employment -2.184 0.772 0.005 -2.049 0.670 0.002
Time×Age 0.004 0.002 0.013 0.005 0.002 0.002
SSM 3 Intercept 27.324 2.057 <0.001 25.824 1.707 <0.001
Time -0.645 0.111 <0.001 -0.730 0.107 <0.001
Age -0.007 0.034 0.830 0.019 0.029 0.517
Employment -2.706 1.087 0.013 -2.044 1.087 0.060
Time×Age 0.002 0.002 0.425 0.00003 0.002 0.990
1 Treat with SERT, continue SERT if respond, otherwise add CBASP to SERT
2 Treat with SERT, continue SERT if respond, otherwise add BSP to SERT
3 Treat with SERT, continue SERT if respond, otherwise add MED to SERT
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Table 3.7: Comparisons of estimated time effects of treatment regimes for a pa-
tient of 43 years controlling for employment status in the REVAMP study.
Method Regime Estimated Effect χ22 p-value
Complete-Case SSC 1 -0.865 + 0.004×43 1.384 0.500
SSB 2 -0.931 + 0.004×43
SSM 3 -0.645 + 0.002×43
IPWGEE SSC 1 -0.882 + 0.004×43 2.028 0.363
SSB 2 -0.955 + 0.005×43
SSM 3 -0.730 + 0.00003×43
1 Treat with SERT, continue SERT if respond, otherwise add CBASP to SERT
2 Treat with SERT, continue SERT if respond, otherwise add BSP to SERT
3 Treat with SERT, continue SERT if respond, otherwise add MED to SERT
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4.0 CONCLUSION
4.1 SUMMARY
In this dissertation, we have demonstrated the estimation of the effects of treatment regimes
in two-stage longitudinal studies in the presence of missing data. To estimate the effect
of a regime from a two-stage longitudinal study with missing data, we have adapted the
inverse-probability-weighted generalized estimating equations (IPWGEE) method to correct
the bias that is caused by missing data.
In Chapter 2, we constructed the weights based on the probability of receiving treatment
and the probability of having complete data at patient level. The probability of receiving
treatment was known by study design and the probability of having complete data was esti-
mated from the sample through a logit model. We showed that under certain assumptions,
the IPWGEE estimators are consistent and asymptotically normal. We also showed how to
compare the treatment regimes via the Wald test, which required computation of covariance
between two estimated regime effects.
In Chapter 3, we have extended the results one step further from Chapter 2. Previously,
patients with incomplete data were ignored. In Chapter 3, we incorporated the information
on the time to response and the time to drop-out. We constructed the weights at visit level.
This allowed us to utilize more observations from patients who dropped out from the study
or patients who were not consistent with the treatment regime to estimate the parameters
of interest with larger efficiency.
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4.2 FUTURE WORK
Our proposed IPWGEE estimators in two-stage longitudinal studies provided valid estima-
tion when the missing data mechanism is missing at random. The efficiency of the proposed
IPWGEE estimators can be improved by incorporating partially observed information from
patients who have missing data due to randomization and drop-out.
The IPWGEEmethod used in Chapter 2 and 3 require the assumption that both marginal
mean model and missing data model to be correctly specified. However, the combination of
the two model specification requirements will increase the chance of at least one misspecifi-
cation and lead to bias. Doubly robust estimating equations [Scharfstein et al., 1999, van der
Laan and Robins, 2003, Bang and Robins, 2005] can provide unbiased estimators as long as
either one of the preceding models is correctly specified. Developing doubly robust weighted
estimating equations in two-stage longitudinal studies will be the basis of our future research.
4.3 PUBLIC HEALTH SIGNIFICANCE
Mental illness is becoming a major public health challenge. Strategies of multiple treatments
have been introduced by many investigators to serve as an alternative to single strategy
in treating patients with chronic depressive disorders. As the complexity of study design
increases, developing sophisticated statistical method is necessary in order to provide valid
inference. This dissertation demonstrates the importance of statistical aspects to estimate
the effects of depression treatment regimes from two-stage longitudinal studies.
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